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LD50 Lethal dose for 50% deaths 
LM Loading module 
LTTR LysR-type transcription regulator 
LPS Lipopolysaccharide 
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MS Mass spectrometry 
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Zusammenfassung 
Teil A: Virulenzregulation in pathogenen Yersinien 
Enteropathogene Yersinien verwenden ein Adhesin namens Invasin, um die 
Darmepithel zu überwinden und in den Körper des Wirts zu gelangen. Dieses Protein 
wird von dem Transkriptionsfaktor RovA reguliert. RovA fungiert als zentrale 
Schaltstelle in einem komplizierten Regulationsnetzwerk, das mehrere Proteine und 
RNAs umfasst. Besonders interessant ist seine Fähigkeit als Proteinthermometer zu 
fungieren. Das bedeutet, dass RovA bei erhöhter Temperatur eine 
Konformationsumwandlung durchläuft, welche zu niedrigerer DNA-Bindungsaffinität 
und verstärktem Abbau durch Proteasen führt.  
 
In dieser Arbeit wurde RovA strukturell und biochemisch untersucht, um ein besseres 
Verständnis dieses komplexen Regulationsnetzwerkes zu entwickeln. Die Struktur 
von RovA im Komplex mit DNA wurde bei 1.9 Å Auflösung gelöst. Diese zeigt nur 
wenige basenspezifische Interaktionen. Dies erklärt die geringe Selektivität von RovA 
für die DNA und somit wie RovA an unterschiedliche DNA-Sequenzen im Genom 
binden kann. Weiterhin wurde entdeckt, dass mehrere kleine Moleküle wie z.B. 
Salicylsäure mit millimolarer Affinität an RovA binden können, was zu reduzierter 
DNA-Bindeaffinität und temperaturabhängiger Konformationsumwandlung führt. Um 
diese Effekte auf molekularer Ebene verstehen zu können, wurde auch die Struktur 
von RovA im Komplex mit Salicylsäure gelöst, in der zwei Bindestellen für 
Salicylsäure pro Monomer RovA identifiziert werden konnten. Die Bindung von 
Salicylsäure führt zu einer Konformationsänderung gegenüber der DNA-gebundenen 
Form.  Dies erklärt, warum die DNA-Affinität von RovA mit Salicylsäure niedriger ist. 
Darüberhinaus wurde in dieser Arbeit noch RovM, ein weiteres Protein aus diesem 
Regulationsnetzwerk biophysikalisch untersucht. RovM ist ein LysR-ähnlicher 
Transkriptionsfaktor, der in der RovA Promoterregion bindet und dadurch die 
Produktion von RovA verhindert. Es konnte gezeigt werden, dass Volllänge RovM ein 
Tetramer bildet, während die Effektorbindedomäne von RovM (RovM-EBD) in 
Lösung als Dimer vorliegt. Die Struktur von RovM-EBD wurde gelöst, welche aus 
zwei Domänen besteht. Zwischen diesen befindet sich eine Öffnung, in der 
möglicherweise ein Induktormolekül binden kann. 
ZUSAMMENFASSUNG  9 
Teil B: Polyketidsynthasen 
Der zweite Teil dieser Arbeit behandelt die Strukturaufklärung von Proteinen, die an 
der Synthese von Polyketiden beteiligt sind. Polyketide sind Naturstoffe, die viele 
Anwendungen in der Medizin finden, z.B. als Antibiotika. Sie werden von riesigen 
Multienzymkomplexen namens Polyketidsynthasen hergestellt, die die Polyketide wie 
am Fließband schrittweise aus kleinen Bausteinen, sogenannte 
Erweiterungseinheiten, zusammensetzen. 
 
Solche Erweiterungseinheiten werden oft von speziellen Enzymen, sogenannten 
Crotonyl-CoA Carboxylasen/Reduktasen (CCR), produziert. Diese katalysieren die 
reduktive Carboxylierung von Crotonyl-CoA zu der typischen Erweiterungseinheit 
Ethylmalonyl-CoA. Allerdings gibt es auch Proteine, die andere, ungewöhnliche 
Erweiterungseinheiten herstellen, wie z.B. Hexylmalonyl-CoA. In dieser Arbeit wurde 
eine solche Karboxylase/Reduktase (CinF), die die Konvertierung von Oktenoyl-CoA 
zu Hexylmalonyl-CoA katalysiert, strukturell und biochemisch untersucht. Die Struktur 
von CinF wurde alleine und im Komplex mit den Liganden NADP und Oktenoyl-CoA 
gelöst. So war es möglich, einen Reaktionsmechanismus für diese ungewöhnliche 
Karboxylierungsreaktion zu postulieren und Aminosäuren zu bestimmen, die für die 
Auswahl der Substrate zuständig sind. Dadurch könnte es möglich werden, diese 
Proteine umzuprogrammieren, sodass sie andere Erweiterungseinheiten 
bereitstellen. Diese könnten dann verwendet werden, um neuartige Medikamente mit 
verbesserten Eigenschaften herzustellen. 
 
Weiterhin wurde die Thioesterase-Domäne aus dem Spirangien PKS 
Biosyntheseweg (SpirTE) kristallisiert. Während der Produktion bleiben die 
Polyketide die ganze Zeit kovalent über eine Thioesterbindung an die PKS-Proteine 
gebunden. Die TE-Domäne katalysiert die Abspaltung des fertigen Produkts vom 
Protein im letzten Schritt, wobei es häufig auch zu einer Zyklisierung des Produkts 
kommt. SpirTE hingegen setzt ein lineares Produkt frei. Das Ziel dieses Projekts ist 
es, auf struktureller Ebene zu erklären, warum manche TE-Domänen eine 
Zyklisierung bewirken und andere nicht. Die Struktur von SpirTE zeigt einen 
Substrattunnel, der sich durch das ganze Protein zieht und in der Mitte das aktive 
Zentrum beherbergt. Verglichen mit anderen TE-Domänen ist dieser Tunnel deutlich 
schmaler, was verhindert, dass das Produkt zyklisiert. 
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Summary 
Part A: Virulence regulation in pathogenic Yersiniae 
Enteropathogenic Yersiniae use an adhesin called invasin for initial penetration of the 
intestinal barrier to reach the interior of the host. This protein, among many others, is 
regulated by the global transcription factor RovA. It is the major player in an intricate 
regulatory network comprising several proteins and RNAs. An interesting observation 
was that RovA could act as a protein thermometer. This means that it undergoes a 
conformational change in response to an increase in temperature which leads to 
reduced DNA binding affinity and increased susceptibility to proteolytic degradation.  
 
In this work, structural and biochemical methods were used to gain a deeper insight 
into the complex regulation by RovA. The structure of RovA in complex with DNA 
was solved at 1.9 Å resolution showing how RovA interacts with the DNA. The few 
specific interactions with the bases of the DNA explain how RovA can bind to several 
different binding sites in the bacterial genome. Several small molecules such as 
salicylate were found to bind to RovA with millimolar affinity and reduce its DNA 
binding affinity as well as its temperature dependent conformational change. In order 
to understand these effects on a molecular level, the structure of RovA in complex 
with salicylate was solved at 2.4 Å resolution. This showed two salicylate molecules 
bound per RovA monomer. Salicylate binding leads to a small conformational change 
compared to the DNA bound structure which might account for the reduced DNA 
binding affinity in the presence of salicylate. 
 
Additionally, another protein from this regulatory network, RovM, was analysed 
biophysically in this work. RovM is a LysR-type transcription factor that binds to the 
RovA promoter and thereby inhibits RovA production. It was possible to show that full 
length RovM is a tetramer in solution, whereas its effector binding domain (RovM-
EBD) exists as a dimer. Furthermore, the structure of RovM-EBD was determined at 
2.4 Å resolution comprising two domains. A cavity was detected between the two 
domains that could bind a potential inducer molecule. 
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Part B: Polyketide synthases 
The second topic of this thesis deals with the structural investigation of proteins 
involved in polyketide synthesis. Polyketides are natural products, often from soil 
bacteria, that have many applications in medicine for example as antibiotics. They 
are produced by huge multi-enzyme complexes called polyketide snythases (PKS). 
These assemble polyketides in a step by step manner from small building blocks, 
similar to an assembly line.  
 
The building blocks, called extender units, are often generated by dedicated 
enzymes, called crotonyl-CoA carboxylase/reductases (CCR). These catalyse the 
reductive carboxylation of crotonyl-CoA to yield the typical extender unit ethyl-
malonyl-CoA. However, recently carboxylase/reductases have been described that 
produce other, unusual building blocks such as hexyl-malonyl-CoA or chloro-ethyl-
malonyl-CoA. In this work, structural and biophysical analysis of such an unusual 
carboxylase/reductase enzyme (CinF) that catalyses the conversion of octenoyl-CoA 
to hexyl-malonyl-CoA has been undertaken. The structure of CinF was solved alone 
and in complex with its ligands NADP and octenoyl-CoA. This represents the first 
structure of such an enzyme in complex with its ligands. It was possible to propose a 
reaction mechanism for this unusual carboxylation reaction and to determine amino 
acids that are involved in the selection of the substrate. Therefore it might become 
possible to reprogram carboxylase/reductases to process novel extender units which 
could be incorporated into new drugs with enhanced properties.  
 
Additionally, the thioesterase domain from the spirangien PKS biosynthesis cluster 
(SpirTE) was crystallized. During polyketide synthesis the polyketide stays covalently 
bound to the PKS proteins at all times via a thioester. TE domains catalyse the last 
step in polyketide synthesis where they cleave this thioester link to release the final 
product and often also catalyse the cyclisation of the product. SpirTE, on the other 
hand, releases a linear product. The aim of this project was to understand on a 
structural level why some TE domains catalyse cyclisation of the product and some 
do not. The structure of SpirTE showed a substrate tunnel spanning the whole of the 
protein which harbours the active site in the middle. Compared to structures of TE 
domains which catalyse cyclisation SpirTE has a much more constricted substrate 
tunnel which could prevent the looping of the substrate and thereby its cyclisation. 
12  INTRODUCTION 
1 Introduction 
 
1A Virulence regulation in pathogenic Yersiniae 
 
1A.1 The plague 
The genus Yersinia is very infamous due to its role in the plague pandemics which 
killed perhaps up to 100 million people worldwide in the 14th century. Originating in 
central Asia, the pandemic, then called Black Death, spread throughout Asia, Europe 
and Africa, reducing the population of Europe by 1/3 with substantial impact on 
European politics, culture and religion (Stenseth et al. 2008). However, there had 
been severe outbreaks of the plague before that, e.g. the so called Justinian plague 
in the 6th century, which killed about half of the population in Europe and is thought to 
have facilitated the Arab conquest of North Africa and Spain. Some sources even 
describe outbreaks of the plague in Greece possibly caused by Yersinia infections 
that date back to 430 BC (Perry & Fetherston 1997).  
 
Though today the hygienic conditions in most parts of the world have improved 
substantially and the disease is treatable with antibiotics, the plague is still endemic 
in some parts of the world, mostly Africa. There it continues to be a threat with 
several thousand reported cases every year. Especially worrying is the emergence of 
multi-drug resistance (Galimand et al. 1997). The plague has also been tested as a 
biological weapon by the Japanese Army in World War II (Harris 1994). Aerosol 
dissemination of the plague in densely populated areas for example by a terrorist 
attack would lead to over 100,000 infections and several 10,000 fatalities (Inglesby et 
al. 2000). Thus, even today the plague remains a considerable concern. 
 
1A.2 Yersinia 
The plague is caused by a member of the bacterial genus Yersinia, called Yersinia 
pestis. The genus Yersinia is part of the family of Enterobacteriacea and was named 
after the Swiss bacteriologist Alexandre Jean Emile Yersin (1863-1943) who 
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discovered Yersinia pestis as the causative agent of the bubonic plague (Perry & 
Fetherston 1997). Yersinia bacteria are facultative anaerobic, Gram-negative rod 
shaped bacteria with a length of a few micrometers (Fig. 1A/B). Yersiniae are 
psychrophilic, which means that they can not only survive, but proliferate at low 
temperatures such as 4°C. 
 
Only two other members of this genus, Yersinia enterocolitica and Yersinia 
pseudotuberculosis cause infections in humans, whereas the others are thought to 
be environmental species (Sulakvelidze 2000). Y. enterocolitica and Y. 
pseudotuberculosis are transmitted via the fecal-oral route and cause gut-related 
symptoms such as diarrhoea (Wren 2003). These infections are relatively harmless 
for humans but especially Y. pseudotuberculosis can lead to devastating losses in 
animals, such as cattle (Tauxe 2004). Interestingly, Y. pestis is most closely related 
to Y. pseudotuberculosis and is thought to have developed from it 1,500 – 20,000 
years ago (Achtman et al. 1999). This is surprising as Y. pestis causes a very 
different disease with a different infection route than Y. pseudotuberculosis. The main 
differences between these species are the inactivation of proteins required for entry 
via the intestine and acquisition of two additional virulence plasmids allowing 
transmission via fleas and systemic dissemination. This makes Y. 
pseudotuberculosis a good model for studying Y. pestis and bacterial pathogen 
evolution.  
 
 
 
Fig. 1: Yersinia bacteria on host cells. A: Yersinia pseudotuberculosis YPIII on the surface of HEp-2 
epithelial cell. With courtesy of Petra Dersch. B: Yersinia enterocolitica on the surface of HEp-2 
epithelial cell. With courtesy of Frank Uliczka and Manfred Rohde. 
 
A B 
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1A.2 Yersinia pestis  
Y. pestis is transmitted mainly via fleas and spreads with infected rodents such as 
rats (Fig. 2) (Wren 2003). Once inside the human body, the bacteria travel to the 
lymph nodes where they cause an inflammation leading to painful swellings called 
bubo (bubonic plague) (Zhou & Yang 2009). In some cases the disease can spread 
to the lung (secondary pneumonic plague) and can then be transmitted to other 
humans via droplet infection (leading to primary pneumonic plague). The 
development of pneumonic plague goes along with a severely decreased chance of 
survival (14% vs. 57% fatality rate of bubonic vs. pneumonic plague) (Inglesby et al. 
2000). A minority of patients also develops a sepsis by Y. pestis without forming 
bubos (septicemic plague).  
 
 
Fig. 2: Infection routes of pathogenic Yersinia. Y. pestis is transmitted by flea from animal 
reservoirs such as rats. The bacteria travel to the lymph nodes causing swelling due to the 
inflammation (bubonic plague). They can also travel to the lungs, where they establish the pneumonic 
plague which can be spread to other humans via droplet infection. The enteropathogenic Yersiniae 
are ingested with contaminated food or water and cross the intestinal barrier to infect the underlying 
lymph nodes. This leads to a localized infection causing gut-related symptoms such as enteritis or 
diarrhoea (adapted from(Wren 2003)). 
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1A.3 Enteropathogenic Yersiniae 
The enteropathogenic Yersinia species Y. pseudotuberculosis and Y. enterocolitica 
are usually taken up by contaminated food, such as raw pork or water (Fig. 2) (Dube 
2009). After passage into the intestine, the bacteria adhere to the mucosal surface, 
are then taken up by M-cells and are transported to the underlying lymphoid tissue, 
the Peyer´s patches (early stage of infection) (Heroven & Dersch 2010). From the 
Peyer´s patches the bacteria migrate to the liver and spleen, where they replicate 
extracellularly and lead to inflammation (late stage of infection) (Trulzsch et al. 2007). 
This entails the typical symptoms such as enteritis, mesenteric lymphadenitis and 
watery or bloody diarrhoea (Koornhof et al. 1999). Different sets of virulence factors 
are required for early and late phase infection, respectively (Fig. 3). Initial adhesion 
and invasion into cells are mediated by an outer membrane protein called invasin. It 
binds tightly to β1- integrins, membrane receptors on the surface of human cells 
required for contact to extracellular matrix proteins such as laminin (Eble et al. 1998). 
In early phase infection and outside the host, the bacteria also need smooth 
lipopolysaccharide (LPS) and flagellar motility (Heroven & Dersch 2010). The early 
phase virulence factors are thus only produced at moderate temperatures. At higher 
temperatures in the host, these genes are repressed and the late phase virulence 
factors are expressed. Most of the late phase virulence genes are encoded on the 
Yersinia virulence plasmid pYV. They comprise the Yersinia adhesin A YadA (El 
Tahir & Skurnik 2001) and the components of the type III secretion system (Ysc, 
Yersinia secretion) as well as the corresponding effector proteins (Yop, Yersinia outer 
protein) (Heesemann et al. 2006; Matsumoto & Young 2009). The latter are injected 
into phagocytic cells and subvert several host cell components such as the actin 
skeleton to prevent phagocytosis (Trosky et al. 2008).  
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Fig. 3: Route of infection for enteropathogenic Yersinia. In the early phase of infection the 
bacteria use flagella and invasin to cross the intestinal barrier to reach the Peyer`s patches. During 
the later phases the bacteria reach the liver and spleen and use YadA for adhesion and the type III 
secretion system and the corresponding effectors to prevent phagocytosis (Heroven & Dersch 2010). 
 
1A.4 RovA, a global virulence regulator 
The expression of the early phase virulence factor invasin (inv) is tightly regulated in 
response to several environmental cues by a complicated regulatory network 
featuring several proteins and regulatory RNAs. The central node in this network 
where all the different influences are integrated is the protein RovA (regulator of 
virulence A) (Revell & Miller 2000). RovA belongs to the MarR-type family of 
transcription regulators that are involved in adaption to the environment, stress and 
virulence, with a central winged-helix DNA binding motif. RovA is mostly known to 
regulate invasin expression in enteropathogenic Yersinia, yet it also plays an 
important role in virulence regulation in Y. pestis which does not contain a functional 
inv gene. rovA mutants in Y. pestis have been shown to lead to improper membrane 
construction (Yang et al. 2010), reduction of pH 6 antigen expression (Cathelyn et al. 
2006) and a significantly higher LD50 compared to the wild type (Ellison et al. 2004). 
Also, in enteropathogenic bacteria, RovA regulates many more genes than inv 
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(Cathelyn et al. 2007). This leads to a much more severe phenotype of rovA mutants 
compared to inv mutants (Nagel et al. 2001; Revell & Miller 2000).  
 
1A.5 RovA regulation 
The rovA gene in Y. pseudotuberculosis is expressed via two promoters P1 and P2 
which are 76nt and 343nt upstream of the transcription start site. At 28°C RovA binds 
to an AT-rich sequence upstream of P2 and thereby activates its own production 
(Heroven et al. 2004). There is an additional, low affinity binding site downstream of 
P1, which acts like an overpressure valve. RovA binding to this site leads to reduced 
transcription of rovA and prevents ever-increasing RovA production by its own 
positive feedback loop (Fig. 4). There is evidence that RovA might directly interact 
with the RNA polymerase to promote transcription of regulated genes (Tran et al. 
2005), yet probably much more important is that RovA competes with the histone-like 
nucleoid structuring protein H-NS for binding at the rovA and inv promoter regions 
(Ellison & Miller 2006; Heroven et al. 2007). H-NS also binds to AT-rich sequences 
and is thought to silence gene expression by binding cooperatively to the DNA and 
either bridging separate DNA segments or inducing a loop in a single binding site 
(Dame et al. 2005; Noom et al. 2007). In the rovA as well as the inv promoter region, 
the binding sites of H-NS and RovA superpose and thus, counteracting H-NS 
repression seems to be the primary way RovA activates gene expression (Heroven et 
al. 2004; Tran et al. 2005).  
 
1A.6 RovA is a protein thermometer 
RovA, and thereby invasin production are dependent on several environmental 
conditions such as temperature, pH and growth phase of the bacteria (Nagel et al. 
2001). RovA is only expressed at moderate temperatures (2-25°C), but not at 37°C. 
This is due to the unique feature of RovA to act as a protein thermometer (Herbst et 
al. 2009). At moderate temperatures RovA binds to its own promoter region and thus 
activates its own transcription. Yet, at 37°C, RovA  undergoes a reversible 
conformational change, which strongly reduces its DNA binding capacity (Fig. 4). 
Additionally, the protein is now susceptible to proteolytic degradation by e.g. the Lon 
protease (Herbst et al. 2009). This leads to strongly reduced RovA and thus invasin 
production. Thus, after being taken up by the host (temperature shift to 37°C) and 
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penetration of the intestinal barrier, the early virulence genes (e.g. inv) are 
downregulated to prevent recognition by the immune system.  
 
Additionally, this thermosensing mechanism is subject to the growth phase of the 
bacteria (Heroven & Dersch 2010). While RovA is highly unstable at 37°C during 
exponential phase, it is stabilised at stationary phase. This growth phase effect might 
be due to the production of a small molecule during stationary phase which binds and 
stabilizes RovA (personal communication Petra Dersch). 
 
 
Fig. 4: Temperature regulated RovA expression. At 25°C RovA binds to its own promoter region 
activating its own transcription by alleviating H-NS mediated repression. This allows production of 
invasin and therefore host invasion. At 37°C the DN A binding capability of RovA is strongly reduced 
and it gets replaced by H-NS. Additionally, RovA is proteolytically digested by the Lon protease. This 
silences inv expression.  
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1A.7 RovM, an inhibitor of RovA 
Another important component of this regulatory network is the LysR-type transcription 
regulator (LTTR) RovM (Heroven & Dersch 2006). LTTR proteins consist of two 
domains, an N-terminal winged helix-turn-helix (wHTH) DNA binding domain (DBD) 
and a C-terminal effector binding domain (EBD) linked by a long and flexible linker 
helix. Different oligomeric states have been observed for LTTR proteins: dimers 
(Zhou et al. 2010), tetramers (Monferrer et al. 2010; Muraoka et al. 2003), and 
octamers (Sainsbury et al. 2009). As a tetramer these proteins have two distant 
DBDs and are thought to bend the DNA around the protein (Deghmane et al. 2004). 
This leads to exposure of nucleotides in between, which then become accessible in a 
DNAseI protection assay (hypersensitive nucleotides). This has been shown to be 
also the case for RovM (Heroven & Dersch 2006), which binds to a region 50nt 
upstream of the rovA P1 promoter. In several cases it was observed that LTTRs 
downregulate their own expression (Schell 1993). In contrast, RovM seems to 
upregulate its own expression via an indirect mechanism (Heroven & Dersch 2006). 
 
RovM acts together with H-NS to repress rovA transcription but in the absence of H-
NS RovM is not able to repress rovA transcription. The main task for RovM seems to 
be the control of RovA (and thus early virulence genes such as inv) in response to 
nutrient availability (Heroven et al. 2007). Under conditions of low nutrient availability 
rovM is expressed, whereas rovA expression is repressed and vice versa. The signal 
for nutrient availability is relayed to RovM via the carbon storage regulator system 
(Csr) (Fig. 5) (Heroven et al. 2008). This system comprises one RNA binding protein 
CsrA and two regulatory RNAs CsrB and CsrC. The CsrA protein is responsible for 
activation of rovM expression by an indirect mechanism. The RNAs CsrB and CsrC 
bind several CsrA molecules and sequester them, preventing rovM activation. The 
production of CsrC is strongly regulated in response to growth phase and media 
composition, whereas the environmental signal for CsrB has yet to be determined. 
RovM has also been shown to be involved in regulating flagellar motility (Heroven & 
Dersch 2006).  
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Fig. 5: Nutrient availability controls expression of early virulence genes via the carbon storage 
regulator (Csr) system and RovM. CsrB and CsrC bind to CsrA, sequestering it and preventing its 
activation of rovM expression. RovM can bind to the rovA promoter region in cooperation with H-NS 
to repress RovA and thereby Invasin production. With courtesy of Petra Dersch. 
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1B Polyketide synthases 
 
Since ancient times, natural products have been used to treat illnesses. For example 
extracts from the bark of the willow tree were recognized to have an effect on fever 
and pain by the Greek physician Hippocrates. These findings led to the development 
of the drug acetylsalicylic acid, Aspirin, at the end of the 19th century. Another 
keystone in the development of modern drugs was the isolation of penicillin by Sir 
Alexander Fleming in 1928. With penicillin it was possible for the first time to 
effectively treat bacterial infections. Since then many different antibiotics have been 
discovered and developed and as a result bacterial infections nowadays do not pose 
such a serious threat as they used to. Yet, some bacteria are notoriously difficult to 
treat such as Mycobacterium tuberculosis, the causative agent of tuberculosis 
(Becerra et al. 2010). Especially worrying is the progressive spreading of multi-drug 
resistant bacteria strains, such as MRSA, methicillin-resitant Staphylococcus aureus 
(Boucher et al. 2010), and Pseudomonas aeruginosa (Hirsch & Tam 2010), both of 
which are virtually untreatable with common antibiotics and often leave the 
physicians with very few options. Thus, it is important to find novel antibiotics that are 
effective against multi-drug resistant bacteria. 
 
1B.1 Streptomycetes 
Most antibiotics originate from natural sources and are then chemically altered to 
enhance their properties such as efficacy. The most yielding source of antibiotics 
have been Streptomyces species (Wilkinson & Micklefield 2007). Streptomycetes are 
gram-negative bacteria from the order of Actinomycetales, which also comprises the 
pathogens M. tuberculosis and C. diphtheriae (Fig. 6). Streptomycetes are 
characterised by their very large, GC-rich genomes, containing more predicted genes 
than, for example, Saccharomyces cerevisiae (Bentley et al. 2002). They are mostly 
found in the soil and are responsible for the earthy smell of soil because of the 
production of a volatile substance called geosmin (Jiang et al. 2006). Over 500 
species of Streptomycetes are known so far and a few of them can cause infections 
in humans (Quintana et al. 2008) and in plants (Lerat et al. 2009).  
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Yet, the most interesting feature of Streptomycetes is their complex secondary 
metabolism. Two thirds of all antibiotics used today, such as chloramphenicol, 
tetracycline and streptomycin have their origin in streptomyces bacteria (Fig. 7). 
These antibiotics are probably produced to defend their ecological niche against 
other bacteria (Thompson et al. 2002). Streptomycetes also produce other 
pharmaceutically valuable molecules such as immunomodulators (rapamycin) and 
anti-cancer drugs (doxorubicin). Therefore, these bacteria are continuously screened 
for novel antibiotics and other useful molecules which could be used for example as 
anti-cancer drugs (Wilkinson & Micklefield 2007).  
 
 
Fig. 7: Antibiotics produced by Streptomycetes: A: Chloramphenicol (S. venezuelae), B: 
Tetracyclin (S. aureofaciens), C: Streptomycin (S. griseus) 
 
 
 
 
Fig. 6: Streptomyces colony morphology and pigmentation. A: Streptomyces colonies isolated from 
soil, producing colored pigments. B: Streptomyces coelicolor colonies with peripheral and aerial mycelia 
producing the blue antibiotic actinorhodin. (Thompson et al. 2002) 
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1B.2 Polyketide synthases 
Most of these molecules are at least partially produced by so called polyketide 
synthases (PKS). PKSs are huge multi-enzyme complexes, that build up polyketides 
in a step-by-step manner, similar to an assembly line (Weissman & Muller 2008). 
They are organized in so-called modules, each responsible for the recognition and 
addition of one specific building block, called extender unit, to the growing chain 
(Khosla et al. 2009). The first module (loading module, LM) recognizes one specific 
building block (starter unit), usually a fatty acid-coenzyme A (CoA) ester and 
transfers it via an acyltransferase (AT) domain onto a acyl-carrier domain (ACP) (Fig. 
8). The ACP domain is post-translationally modified by the addition of a 
phosphopantheteine (PPant) residue to a conserved serine by phosphopantheteine 
transferases (Lambalot et al. 1996). This PPant-“arm” is very flexible and able to 
reach the different domains of the protein and has a thiol group at its end (Lai et al. 
2006). The starter unit is bound to this thiol group as a thioester by a trans-
esterification reaction from the CoA region of the starter unit, which is then released.  
 
The bound starter unit is then transferred to the next module which has already 
bound an extender unit (usually a carboxy- fatty acid-CoA ester) at its ACP domain. 
The starter unit from the first module is then added to the extender unit from the 
second module via a thioclaisen condensation in the ketosynthase (KS) domain of 
the second module, which sets free the “empty” ACP of the first module. The product 
is then transferred to the next module, where a new extender unit is added to the 
chain and so forth. During this whole process, the growing chain is covalently bound 
to an ACP domain of the PKS complex. This so called “substrate channelling” is 
important to ensure rapid production of the molecule and stabilisation of possibly 
instable intermediates (Spivey & Ovadi 1999). In the end, the polyketide is detached 
from the ACP of the last module by a thioesterase domain. This domain cleaves the 
thioester and often promotes cyclisation of the product (Akey et al. 2006).  
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Fig. 8: Modular organization of PKS systems. A loading module (LM), consisting of a 
acyltransferase (AT) domain and an acyl carrier protein domain (ACP), binds the starter unit and 
transfers it to the first extension module (EM1). EM1 is a minimal module, containing also a 
ketosynthase (KS) domain, responsible for connecting the starter unit with the first extender unit. The 
second extension module (EM2) contains additional reductive domains (ketoreductase (KR), 
dehydrogenase (DH) and enoylreductase (ER), leading to a fully reduced methylene group instead of 
a keto group. A terminal thioesterase (TE) domain finally cleaves off the product from the protein and 
may catalyse cyclisation of the product. (Weissman & Muller 2008) 
 
Thus, a typical PKS module consists of an AT, an ACP and a KS domain. In addition 
to which, there can be for example a ketoreductase (KR) domain, which reduces the 
keto group of the freshly added extender unit to an alcohol (Fig. 8). This can then be 
reduced to a double bond by a dehydrogenase (DH) domain and further to a fully 
reduced methylene group by an additional enoylreductase domain (ER). Additional 
tailoring can be done by methylase domains.  
 
The reactions catalysed by PKSs are reminiscent of the related fatty acid synthases 
(FAS), yet the FAS can only do one set of reactions over and over to produce a 
uniform product (Maier et al. 2008). On the other hand, the modular architecture of 
PKS, where every module is capable of using a different extender unit, augmented 
by the variety of possible reductases and further tailoring allow PKSs to produce a 
huge variety of different molecules. The product of one PKS is often already obvious 
from the arrangement of the genes in the biosynthetic cluster (Challis et al. 2000). 
This makes PKS valuable targets for bioengineering efforts to change for example 
the arrangement of the modules and thus the structure of the product, allowing the 
production of altered versions of known drugs to enhance their properties to create 
completely novel molecules (Gokhale et al. 2007). Unfortunately, structural 
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information about PKS systems is still scarce, hampering rational engineering of 
these proteins. 
 
1B.3 Cinnabaramides - potential new anti-cancer drugs 
Extracts from Streptomycetes are continuously screened for interesting biological 
activities, such as antibiotic activity or anti-tumor activity. Recently, molecules, called 
cinnabaramides, were identified from a streptomyces extract that exhibit a potent 
inhibition of the human 20S proteasome (Fig. 9B) (Stadler et al. 2007). These 
molecules are very similar to salinosporamides from Salinispora tropica, which are 
currently under development as anti-cancer drugs (Fig. 9C) (Chauhan et al. 2005). 
The main difference is the chlorinated butyrate moiety in the salinosporamides is 
replaced by an octanoic residue in cinnabaramides. The gene cluster responsible for 
the production of cinnabaramides contains 19 predicted genes of which six (cinA-F) 
are involved in the cinnabaramide core biosynthesis (Rachid et al. 2011). CinA 
comprises two PKS modules, the first binds acetyl-CoA as a starter unit and the 
second elongates the chain with the unusual extender unit hexylmalonyl-CoA (Fig. 
9A). CinA also contains one domain from a non-ribosomal peptide synthetase 
(NRPS) which work analogous to PKSs, but utilize amino acids as extender units to 
produce small polypeptides. Two other NRPS domains are located in CinB. These, 
together with the NRPS domain in CinA, are proposed to elongate the intermediate 
by a cyclohexenyl-alanine residue. The stand-alone KS domain CinC then catalyses 
the intramolecular condensation to generate the γ-lactam-ring. The thioesterase CinE 
cleaves off the thioester bound intermediate and promotes β-lacton-ring-formation. 
The predicted P450 monooxigenase CinD probably catalyses a hydroxylation to 
produce the β-hydroxy-2-cyclohexenyl-alanine residue in some cinnabaramides.  
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Fig. 9: Cinnabaramide synthesis. A: Scheme showing the biosynthesis of the Cinnabramides. B: 
Cinnabaramide A (R1=OH,R2=H), C: Salinosporamide A (R=Cl) and salinosporamide B (R=H) from 
Salinispora tropica. (Rachid et al. 2011) 
 
1B.4 CinF produces an unusual PKS building block 
The protein CinF shows similarity (50% sequence identity) to a crotonyl-CoA 
carboxylase/reductase (CCR) that generates ethylmalonyl-CoA by reductive 
carboxylation of crotonyl-CoA (Erb et al. 2007). Interestingly, these proteins use 
NADPH and CO2 to catalyse this reaction (Erb et al. 2009). This is unique as usually 
carboxylation reactions require the presence of metals and often biotin and ATP as 
cofactors. Thus, it was proposed that CinF produces the unusual extender unit 
hexylmalonyl-CoA from octenoyl-CoA using NADPH and CO2 (Fig. 10). Another 
protein that is proposed to catalyse this reaction is TgaD, a protein involved in the 
production of thuggacins in the myxobacterium Sorangium cellulosum (Buntin et al. 
2010a). Surprisingly, the sequence identity is very low at only 15%. 
Carboxylases/reductases are very promising targets for bioengineering as changing 
their substrate specificity may allow the production of drugs featuring novel 
functionalities. Yet, such work requires structural information about these proteins 
and their reaction mechanism. This would then lead to the identification of the amino 
acids responsible for substrate specificity and allow rational design of new proteins 
with altered specificity. However, as yet, no structural information about this 
interesting class of proteins has been published. 
 
B 
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Fig. 10: Reaction catalysed by CinF. Octenoyl-CoA is converted to hexylmalonyl-CoA by CinF 
using CO2 and NADPH as cofactors. 
 
1B.5 Spirangienes 
Spirangienes are highly cytotoxic and antifungal molecules, produced by the 
epothilon-producing myxobacteria strain Sorangium cellulosum So Ce90 (Fig. 11A) 
(Niggemann et al. 2005). They contain the characteristic spiroketal core structure 
which is also found in several other pharmaceutically important molecules such as 
avermectins (Albers-Schoenberg et al. 1981). The Spirangien biosynthesis cluster 
comprises 13 genes, coding for seven PKS proteins with a total of 15 modules for the 
production of the spirangien core structure (Frank et al. 2007). Six additional genes 
code for example for methyl transferases and monooxigenases for the tailoring of the 
spirangienes. Of special interest is the thioesterase domain of the last module 15 
(SpiJ) called SpirTE (Fig. 11B). Thioesterase domains are responsible for the 
cleavage of the finished polyketide from the PKS. Most TE domains additionally 
catalyse the cyclisation of the cleaved product. SpirTE on the other hand releases a 
linear product without cyclisation. Understanding the molecular mechanism of TE 
domains is important as the TE domain has to be adapted to the new substrate in 
order to produce novel substances. Structural data is available for cyclising TE 
domains (Akey et al. 2006; Samel et al. 2006; Tsai et al. 2001), yet only recently one 
structure of a non-cyclising TE domain has been published without a substrate 
(Scaglione et al. 2010).  
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Fig. 11: Spirangien biosynthesis. A: Structure of Spirangiens A and B; B: Reaction catalysed by 
SpirTE in the Spirangien biosynthesis (modified from (Frank et al. 2007)) 
A B 
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2 Aims 
2A Virulence regulation in pathogenic Yersiniae 
For efficient invasion into the host, enteropathogenic Yersiniae use the outer 
membrane protein invasin. Its expression is regulated by a complex network of 
regulatory proteins and RNAs in response to a large variety of environmental cues. 
The key protein in this network is RovA as it is directly responsible for invasin 
regulation in response to various signals such as temperature. The main aim of this 
thesis was to determine the structure of RovA alone and in complex with DNA to 
understand its DNA binding mechanism and the promiscuity it shows towards its 
DNA binding sequences. Additionally, the influence of small ligand molecules on 
RovA was to be elucidated structurally and biochemically. Furthermore, by 
comparison of RovA with its homologue SlyA from S. typhimurium the structural and 
functional basis of RovA thermosensing should be analysed. 
The second aim was to determine the structure of RovM, an inhibitor of RovA. The 
structure should explain how RovM links the availability of nutrients, mediated by the 
CSR system, to virulence factor regulation by RovA.  
 
2B Polyketide synthases 
 Engineering polyketide synthase systems promises the possibility of producing tailor-
made molecules which can be used as drugs such as antibiotics. To be able to do 
this efficiently the molecular working mechanisms of these systems have to be 
understood in detail. Therefore, our first goal was to structurally and functionally 
characterise carboxylase/reductase enzymes, which provide the building blocks for 
polyketide synthases by a novel reaction mechanism. We aim to solve the first 
structure of one of these proteins, CinF, in complex with its substrates, to understand 
its unique reaction mechanism. Additionally, the structure should provide insights into 
the determinants of substrate specificity. 
Furthermore, we wanted to solve the structure of SpirTE, a PKS thioesterase domain, 
to understand its reaction mechanism which leads to a linear product instead of a 
typically cyclised product. 
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3 Materials and methods 
 
3.1 Materials 
 
The chemicals that were used in this work were purchased from the following 
companies in the quality p.a. (pro analysis): Eurofins MWG Operon, Fermentas, 
Fluka, GE-Healthcare, Hampton Research, Invitrogen, Merck, Millipore, Qiagen, 
Riedel de Haen, Roche, Roth, Sigma-Aldrich and Stratagene. 
 
3.1.1 Enzymes 
 
Table 1: Enzymes and standards used in this work 
Enzyme Company 
DNase I   Roche 
T4 DNA Ligase  New England Biolabs 
Platinum Pfx DNA Polymerase Invitrogen 
Pfu Turbo polymerase   Stratagene 
Restriction endonucleases:  
NdeI, XhoI 
New England Biolabs 
  
Standards  
Smart Ladder (DNA)     Eurogentec 
Precision  Plus  Protein  All  Blue  
Standards (Protein)  
 
BIO-RAD 
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3.1.2 Kits 
 
Table 2: Kits used in this work 
Kit Company 
QIAprep® Spin Miniprep Kit   Qiagen 
QIAquick® PCR Purification Kit   Qiagen 
QuikChange® Site-Directed Mutagenesis Kit  Stratagene 
 
3.1.3 Screens  
 
The following crystallization screens obtained from Qiagen were used in this work: 
 
Table 3: Crystallization screens used for finding initial crystallization conditions 
The AmSO4   The pHClear   
The Anions   The PACT 
The Cations   ProComplex 
The Classics  I + II JCSG+ 
The Cryo   JCSG Core I-IV 
The PEGs    I + II  
 
The Morpheus screen from Molecular Dimensions was also used, as well as the 
Additive Screen from Hampton Research. 
 
3.1.4 Oligonucleotides 
 
In the following DNA oligonucleotides (primers) are listed that were used in this work. 
These were purchased from Eurofins MWG Operon. The restriction sites are 
underlined and the corresponding restriction enzyme listed. For primers used for 
mutagenesis the desired mutation in the protein is given.  
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Table 4: List of DNA oligonucleotides  
Primer Sequence (5` 3`) Restriction 
enzyme 
Primers used for cloning  
RovM EBD FW gggaattccatatgtacagcaatatggaagg NdeI 
RovM EBD RV aggagactcgaggactacttaatc XhoI 
Primers used for mutagenesis  
ccatggaatcgacattattctctgatctagcacgattag RovA G6F FW 
                  RV ctaatcgtgctagatcagagaataatgtcgattccatgg 
cattaggatctgatctattccgattagttcgcgtttggc RovA A10F FW 
                    RV gccaaacgcgaactaatcggaatagatcagatcctaatg 
 
Oligonucleotides used for determination of minimal RovA binding fragment 
taattgatattatttatatgataatagtt 29 FW 
     RV aactattatcatataaataatatcaatta 
aattgatattatttatatgataatagt 27 FW 
     RV actattatcatataaataatatcaatt 
attgatattatttatatgataatag 25 FW 
     RV ctattatcatataaataatatcaat 
ttgatattatttatatgataata 23 FW 
     RV tattatcatataaataatatcaa 
tgatattatttatatgataat 21 FW 
     RV attatcatataaataatatca 
gatattatttatatgataa 19 FW 
     RV ttatcatataaataatatc 
atattatttatatgata 17 FW 
     RV tatcatataaataatat 
tattatttatatgat 15 FW 
     RV atcatataaataata 
attatttatatga 13 FW 
     RV tcatataaataat 
ttatttatatg 11 FW 
     RV catataaataa 
20a FW gatattatttatatgataat 
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       RV attatcatataaataatatc 
tgatattatttatatgataa 20b FW 
       RV ttatcatataaataatatca 
atattatttatatgataat 19a FW 
       RV attatcatataaataatat 
tgatattatttatatgata 19b FW 
       RV tatcatataaataatatca 
  
Oligonucleotides used for cocrystallization Overhangs 
tgatattatttatatgataa Blunt end Inv1 20   FW 
               RV ttatcatataaataatatca Blunt end 
ttgatattatttatatgataa Blunt end Inv1 21   FW 
               RV ttatcatataaataatatcaa Blunt end 
atgatattatttatatgataa 5`A Inv1 20A FW 
               RV tttatcatataaataatatca 5`T 
aaattgatattatttatatgataata 5`A Inv1 25A FW 
               RV ttattatcatataaataatatcaatt 5`T 
cgatattatttatatgatc 5`C Inv1 19C FW 
               RV cgatcatataaataatatc 5`C 
ggatattatttatatgatc 5`G Inv1 19G FW 
               RV ggatcatataaataatatc 5`G 
atatgataaatgatattattt 3`A Inv1 Art   FW 
               RV aataatatcatttatcatata 3`A 
aatagactgttttattatata 5`A Inv2a      FW 
               RV ttatataataaaacagtctat 5`T 
aataaaacagtctataccata 5`A Inv2b      FW 
               RV ttatggtatagactgttttat 5`T 
aattatattatttgaattaat 5`A rovA1A   FW 
               RV tattaattcaaataatataat 5`T 
tttacatccattaattatata 5`A rovA1B   FW 
               RV atatataattaatggatgtaa 5`T 
tatgctagcacgctaattaaa 5`A rovA2A   FW 
               RV atatgctagcacgctaattaa 5`T 
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3.1.5 Plasmids 
 
Table 5: Plasmids used in this work  
Plasmid GOI Derivation Reference 
pET28-RovA  RovA C81S, 
C108S  
Site directed mutagenesis 
of rovA in pET28a 
This work 
pET28-RovA G6F RovA C81S, 
C108S, G6F 
Site directed mutagenesis 
of pET28-RovA 
This work 
pET28-RovA A10F RovA C81S, 
C108S, A10F  
Site directed mutagenesis 
of pET28-RovA 
This work 
pAKH43 RovM rovM in pET28a Heroven et al 
2006 
pET28-RovM-EBD RovM-EBD rovM-EBD (aa 92-310) in 
pET28a 
This work 
pET28-SpirTE SpirTE spirTE in pET28a Buntin et al. 
2010 
 
3.1.6 Bacterial strains 
 
Table 6: Bacterials strains 
Strain Genotype Company 
Top10 F–, mcr A ∆(mrr-hsdRMS-mcrBC) Φ80 lacZ ∆ M15 
∆lacX74 recA1 araD139 ∆(ara-leu)7697 gal U gal K 
rpsL endA1nupG 
Invitrogen 
XL1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac  
[F´proAB lacIqZ∆M15 Tn10 (Tetr)]. 
Stratagen 
BL21 F- ompT hsdSB(rB– mB–) dcm+ dam+ TetR galλ 
(DE3) endA Hte [argU, ileY, leuW, CmR] 
Stratagen 
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3.1.7 Media and buffers 
 
Table 7: Media and buffer compositions 
Name Composition 
Media  
Luria Bertani (LB) 10 g/L tryptone, 5 g/L, NaCl, 5 g/L yeast extract 
SOC-Medium 20 g/L tryptone, 5 g/L yeast extract, 0.5 g/L NaCl, 2.5 
mM KCl, 10 mM MgCl2, 20 mM glucose 
10x M9 60 g/L Na2HPO4, 30 g/L KH2PO4, 5 g/L NaCl, 10 g/L 
NH4Cl, autoclave separately 
Minimal Medium (M9) 100 ml 10x M9, 0.1 mM CaCl2, 1 mM MgSO4, 20 mM 
glucose, 0.2 % casaminoacids 
  
Buffers  
Bandshift buffer (10%) 100 mM Tris-HCl pH 7.5, 10 mM EDTA, 50 mM DTT, 50 
% Glycerol, 100 mM NaCl, 10 mM MgCl2, 1 mg/ml BSA 
CD buffer  10 mM NaH2PO4, pH 8, 10mM NaCl, 5mM DTT, 1mM 
MgCl2 
DNA loading buffer (10x) 10 mM Tris/HCl, pH 7.5, 0.05% (w/v) bromphenol blue, 1 
mM EDTA, 50% glycerol 
Gel filtration buffer 20mM Tris/HCl pH 8, 100mM NaCl, 5mM DTT 
Lysis buffer 50 mM NaH2PO4 pH 8.0, 300 mM NaCl, 10 mM 
imidazole, 1 mM MgCl2 
Ni-NTA wash buffer 50mM NaH2PO4 pH 8.0, 300mM NaCl, 20mM imidazole 
Ni-NTA elution buffer 50mM NaH2PO4 pH 8.0, 300mM NaCl, 250mM 
imidazole 
RovA Gel filtration buffer 20mM Tris/HCl pH 9, 100mM NaCl, 5mM DTT 
SDS-PAGE Lower buffer 
(4x) 
1.5 M Tris/HCl, pH 8.8 
SDS-PAGE running 
buffer 
25 mM Tris/HCl, 192 mM glycine, 0.1% (w/v) SDS 
SDS-PAGE sample 
buffer (2x) 
1 ml 1 M Tris/HCl pH 6.8, 2.4 mM glycerol, 0.8 g SDS, 2 
mg Coomassie blue G-250, 0.31 g DTT, add H2O to 10 
mL 
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SDS-PAGE separating 
gel 
10 mL Polyacrylamide solution, 5 mL 4 x Lower buffer, 
0.2 mL SDS (10%), 4.7 mL H2O, 20 µL TEMED, 50 µL 
APS (25%) 
SDS-PAGE stacking gel 1.5 mL  Polyacrylamide  solution,  2.5 mL  4  x  Upper  
buffer,  5.9 mL H2O, 15 µL TEMED, 25 µL APS (25%) 
SDS-PAGE Upper buffer 
(4x) 
0.5 M Tris/HCl pH 6.8, 0.4% (w/v) SDS 
TAE buffer 40 mM Tris/HCl pH 8.2, 20 mM sodium acetate, 1 mM 
EDTA 
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3.2 Methods 
 
3.2.1 Standard procedures 
Standard methods used in this work are adapted from collections of methods and 
protocols (Ausubel et al. 2007; Coligan et al. 2002). Only variations of standard 
protocols are described below. 
3.2.2 Protein production and purification 
All proteins in this work were cloned into a pET28 vector and were thus produced and 
purified in a very similar way. A standard protocol is given here and exceptions are 
mentioned where appropriate.  
The vector was transformed into competent E. coli BL21 (DE3) cells and single 
colonies were selected on a Kanamycin-containing (30µg/ml) LB-plate. One colony 
was used to inoculate a 50ml overnight LB culture containing Kanamycin (30µg/ml). 
The next day 2x1L of LB (M9 for RovA) medium were inoculated with 10ml of the 
overnight culture each and grown at 37°C at 160rpm.  At an OD600 of 0.7 the cultures 
were induced with 0.25mM of IPTG and incubated at 20°C over night. Then the cells 
were harvested by centrifugation at 6,000 rpm at 4°C for 10min. The supernatant was 
discarded and the pellet was stored at -20°C. 
3.2.2.1 Production of SeMet-labelled protein 
For the production of Se-Met labeled protein, an overnight culture was grown in LB 
medium as described above. The cells centrifuged at 5.000 rpm for 15min, washed in 
water and centrifuged again. The supernatant was discarded and the cells 
resuspended in minimal medium to an OD600 of 1.0. Selenomethionine was added to 
a final concentration of 15µg/ml medium as well as 0.25mM IPTG to induce protein 
production. The cells were incubated over night at 20°C and subsequently harvested 
by centrifugation. 
3.2.2.2 Protein purification 
The cell pellet was resuspended in 50ml Lysis buffer and DNaseI and a Complete 
Protease Inhibitor Cocktail Tablet (Roche) were added. The cells were lysed two 
times by using a homogenizer at 20kpsi at 4°C. The lysate was cleared from cell 
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debris by centrifugation at 16,000rpm for 45min at 4°C. The supernatant was applied 
to a Ni-NTA column pre-equilibrated with Wash buffer and incubated under mild 
shaking at 4°C for 30min. Unspecifically bound prot ein was removed by washing the 
column with 3 column volumes (about 50ml each) of Washing buffer. The target 
protein was eluted with 4x 15ml Elution buffer. The eluted fractions were tested for 
protein yield and purity by SDS PAGE (15% for RovA, 12% for the other proteins).  
 
The chosen protein fractions were pooled and concentrated to 1ml using Vivaspin 
concentrators with a molecular weight cutoff (MWCO) of 10kDa. For further 
purification and removal of the imidazole the protein was applied to a 16/60 
Superdex200 (SD200) gel filtration column pre-equilibrated with Gel filtration buffer 
(for RovA: RovA Gel filtration buffer). The protein containing elution fractions were 
again tested by SDS PAGE and the fraction containing the pure protein were pooled 
and concentrated to 10mg/ml (50mg/ml for RovA).  
 
3.2.3 Protein analytical methods 
3.2.3.1 SDS polyacrylamide gelelectrophoresis (SDS PAGE) 
SDS PAGE was used to evaluate the purity and yield during the protein production 
(Laemmli 1970). The gels were composed of two parts the upper stacking gel (5% 
acrylamide) and the lower resolving gel (12% or 15% acrylamide). Typically 6µl of 
protein solution together with 6µl of SDS loading buffer were heated for 5min at 90°C 
and then run at constant 40mA per gel on an SDS gel until the dye front reached the 
end of the gel (usually 30min). After the electrophoresis, the gel was washed with 
water to remove SDS and then stained with Instant Blue coomassie dye for 5min. 
3.2.3.2 Mass spectrometry (MS) 
Mass spectrometry (MS) analysis was performed to confirm the identity and the 
correct labeling of the produced proteins using either MALDI-TOF (Matrix Assisted 
Laser Desorption Ionisation – Time Of Flight) or ESI-MS (Electrospray Ionisation). 
These analyses were carried out by Dr. Manfred Nimtz and Undine Felgenträger 
(HZI, Braunschweig). 
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3.2.3.3 Gel shift assay 
Gel shift assays are used to determine the affinity of DNA binding proteins to DNA 
fragments. The DNA is submitted on a native polyacrylamide gel electrophoresis with 
and without protein, where the protein bound DNA is retarded in respect to the free 
DNA due to the increased size.  
Before the experiment the single stranded oligo nucleotides were mixed in an 
equimolar ration, heated to 95°C for 5min and then let cool slowly to allow double 
strand formation. In our studies 150ng of DNA were used together with 7.5µg RovA 
in bandshift buffer and run on an 8% gel at 70V for 40min. Afterwards, the gel was 
stained in ethidium bromide solution (50µl/50 ml) and inspected under UV light. 
3.2.3.4 ThermoFluor assay 
ThermoFluor assays allow rapid screening of the influence of buffer conditions and 
additives on the stability of a protein. It is often used to find a buffer in which the 
protein is most stable. It can also be used to determine the binding affinity of a 
substance to a protein (Saridakis et al. 2008). The protein is mixed with a fluorescent 
dye and heated in 0.5°C steps while the dye fluores cence is recorded. When the 
protein starts to unfold, hydrophobic patches become accessible to the dye. The dye 
is thereby shielded from quenching in the aqueous solution and the fluorescence 
increases. After the melting point protein aggregation reduces the available 
hydrophobic patches and the fluorescence drops slowly. From the resultant curve the 
melting point can be obtained by determining the peak position of the first derivative 
of the fluorescence curve. Comparison of the melting points for different buffer 
conditions reveals conditions in which the protein is most stable.  
For testing of a set of standard buffers a screen similar to that suggested by Niesen 
et al., 2007 was used. The protein (1-2mg/ml end concentration) was diluted in the 
desired buffers and a fluorescent dye (Sypro Orange, 100x) was added. The samples 
were measured in a CFX96 Real-Time Thermal Cycler C1000 (BioRad) in a 96-well 
plate (Multiplate 96-Well Unskirted PCR plate, BioRad) sealed with a non-
fluorescence absorbing seal (Microseal ’B’ Adhesive Seal, BioRad). The 
corresponding CFX software as well as Microsoft Excel were used to analyse the 
data. 
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3.2.3.5 Circular dichroism (CD) 
Circular dichroism is a method for the determination of the secondary structure 
contents of a protein as well as the protein stability. It is based on the differential 
absorption of left and right circularly polarized light by chiral molecules (such as 
proteins). Proteins are usually measured in the UV range and exhibit distinct 
absorption characteristics depending on their content of secondary structure 
elements.  
Before the measurement the protein was diluted to 0.16mg/ml with CD buffer. 
Spectra were recorded from 190nm to 250nm at different temperatures with a J-815 
CD spectrometer (Jasco). For denaturation curves the ellipticity at 208nm and 222nm 
(Minima for alpha helical proteins) was measured with increasing temperatures. 
Evaluation was similar to the melting curves from the thermofluor experiments. 
 
3.2.4 Protein crystallization 
3.2.4.1 Initial screening 
To screen for initial crystallization conditions 0.2µl of the concentrated, pure protein 
(typically 10mg/ml) was mixed with the same volume of reservoir buffer of 
commercially available screens in a 96-well sitting drop vapor diffusion plate using 
the Honeybee 961 crystallization robot (Zinsser Analytics). The plate is sealed using 
a MancoTM Crystal Clear tape (Jena Bioscience) and the drops left to equilibrate 
against the reservoir solution at 16°C. After three  days and the every two days the 
plates were checked for the appearance of crystals with a microscope.  
 
3.2.4.2 Optimization 
Initial crystals were tested for diffraction if possible and further optimized using 24-
well hanging drop vapour diffusion plates. For the optimization several parameters 
such as the protein and precipitant concentration as well as the pH, different drop 
sizes and incubation temperature were varied. Additionally, crystal growth promoting 
additives were tested using the Additive Screen (Hampton Research) and seeding 
techniques such as micro-seeding and streak seeding (for RovA with salicylate, 
SpirTE and CinF) were employed to obtain larger crystals.  
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3.2.4.3 Cryo protection 
X-rays induce the formation of radicals within the crystal during the measurement 
(Garman 2010). These can migrate through the crystal and damage it leading to 
rapid loss of diffraction. This is strongly reduced by freezing the crystals to 100°K (in 
liquid nitrogen). Yet, freezing of aqueous solutions results in ice formation which can 
damage the crystal and reduce the quality of the measured data by its own diffraction 
(ice rings). This is avoided by the addition of cryo protectants such as glycerol, small 
molecular weight PEG or sugars. For most crystals in this work a solution of reservoir 
buffer including 10-20% glycerol was prepared, the crystal transferred from its drop 
into this solution and then quickly frozen in liquid nitrogen. CinF was crystallized in a 
solution already containing glycerol and thus no further cryo protectant was required. 
 
3.2.5 X-ray structure analysis 
3.2.5.1 Diffraction of crystals 
X-ray crystallography allows the determination of protein structures at atomic 
resolution. These structures can be used to elucidate the molecular mechanism of 
enzymes, design of specific protein inhibitors and understand the molecular details of 
protein interactions. For this a single protein crystal of sufficient size is required. This 
crystal is frozen and irradiated with monochromatic X-rays, generated either by a 
rotating anode X-ray generator (homesource) or a synchrotron. While most of the 
rays do not interact with the crystal, a small percentage is diffracted in a certain 
direction with certain intensity and these diffracted rays are measured on a detector 
(typically a CCD device). The crystal is rotated around one axis in small steps (0.5°) 
and one image is recorded for each step. From these recorded images the position 
and the intensity of the diffracted X-rays can be calculated providing information 
about the structure of the protein in the crystal.  
 
In which direction and under which angle an X-ray is diffracted is determined by 
Bragg`s Law, 
 
)sin(2 θλ dn = ,          (equation 1) 
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where n is an integer, λ is the wavelength of incident wave, d is the spacing between 
the planes in the atomic lattice, and θ is the angle between the incident ray and the 
scattering planes. 
 
 
It assumes the presence of sets of (imaginary) planes (called Miller Planes, 
characterized by its three Miller coordinates h, k and l) which are evenly distributed 
throughout the crystal lattice that act as semitransparent mirrors (Fig. 12). Thus if an 
X-ray impinges on one plane from one set it will be reflected by the plane while 
another ray from the same direction will reach the plane below and be reflected by it. 
These two emerging waves will interfere with each other. This interference can only 
be constructive if the difference in the distances these two rays have to travel is equal 
to an integer number times the wavelength. As these sets of planes are considered to 
be infinite even a small phase difference between these two rays will lead to 
destructive interference with a wave coming from a plane much further away. Thus 
for each orientation of the crystal a certain number of planes will fulfill Bragg`s Law 
and produce a measurable diffracted X-ray. From the pattern that is generated by 
these rays, the crystal parameter and symmetry can be deduced.  
 
3.2.5.2 Calculating the electron density  
With the knowledge of the intensity and phase for each reflection, the electron 
density for the unit cell of the crystal can be calculated.  
 
Fig. 12: Diffraction of X-rays from two parallel planes. To produce constructive interference the 
two reflected rays have to be perfectly in phase. This is only true when the distance the second ray 
has to travel more than the first (2*l=2dsinθ) is an integer multiple of the wavelength. 
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where ρ(x,y,z) is the electron density, V is the unit cell volume, |Fhkl| is the structure 
factor amplitude for each reflection (which is equal to the square of the  measured 
intensity) and αhkl are the phases for each reflection. 
 
Unfortunately, the phase information, which carries more information than the 
intensity, is lost during the measurement. As it is impossible to determine the phase 
directly, several indirect methods have been developed to determine the phase (or 
produce a good estimate of it). These methods include single/multiple isomorphous 
replacement (SIR/MIR), molecular replacement (MR), single/multiple wavelength 
anomalous dispersion (SAD/MAD) or combinations thereof. Only SAD and MR will be 
discussed further as these were used in this work. 
 
3.2.5.3 Molecular replacement (MR) 
Molecular replacement is an easy and often quick way to solve the phase problem by 
using phase information obtained from structures of other proteins with a similar fold. 
Obviously, this method suffers from the limitation that a suitable molecular 
replacement model has to be available. Yet, with the quickly growing number of 
protein structures in the Protein Database (PDB) this method becomes ever more 
powerful.  
 
By applying the Fourier back-transformation to an already solved protein structure 
(and thus doing an imaginary diffraction experiment) the phase information for this 
protein can be obtained. Molecular replacement is based on the assumption that 
these phases of a homologous protein will serve as a sufficiently good estimate of the 
real phases. By combination with the measured intensity interpretable density can be 
obtained and further be refined. The main problem in this method is the generation of 
a good MR model and the orientation and positioning of the model. For MR to work, 
the model has to be oriented in the same unit cell in the same way as the unknown 
structure. A brute force approach is computationally very intensive as six parameters 
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(the three position coordinates and the three angles) have to be varied at the same 
time. To accelerate this process, the search for the correct orientation is performed 
first and with the found solution a positional search is done. This reduces one six-
dimensional problem to two three-dimensional problem, which is much less complex. 
The search for the correct orientation (rotation search) uses the correlation between 
the Patterson maps from the known and the desired structure. The Patterson maps 
are generated by the application of the Patterson function, which is very similar to the 
equation 2 used to calculate the electron density, but does not include the phase 
information:  
∑∑∑
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The Patterson maps do not provide information about the absolute position of the 
atoms, but rather the relative distances between the different atoms. This information 
can be enough to solve the phase problem by trial and error for small molecules, but 
not for proteins. Yet, the Patterson map provides information about the orientation of 
the molecule. The Patterson map of the model is calculated for every possible 
orientation and the correlation with the Patterson map of the measured protein is 
calculated. The orientation that correlates best should be the orientation of the 
measured protein.  
 
After the correct orientation has been found, the search for the position of the 
molecule is started (translation search). This search also relies on the calculation of 
Patterson maps with the correctly oriented model in different positions within the unit 
cell. The different symmetry elements are important in this search. Is the desired 
protein in the space group P1, which does not contain any crystallographic symmetry, 
this search is not necessary, as the unit cell can be defined as desired. Once the 
model is in the same orientation and position as the measured protein, the Fourier 
back-transform of the molecule is performed. This provides calculated phases and 
intensities. The intensities are discarded and replaced by the measured intensities. 
Together with the phases, the Fourier transform is calculated and a (hopefully) 
interpretable electron density is obtained. 
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3.2.5.4 Single/multiple wavelength anomalous dispersion (SAD/MAD) 
Another popular technique to obtain phase information is anomalous dispersion. It 
relies on differences between Friedel mates (Fhkl and F-h,-k,-l) that occur when 
wavelengths are used for the diffraction experiment, which are close to an absorption 
edge of an element incorporated in the crystal. Sometimes these elements are 
already present in the protein such as sulfur in cysteines and methionines, prosthetic 
groups such as iron sulfur clusters or bound metal ions. Alternatively, they can be 
introduced during protein production (SeMet labeling) or by soaking of a native 
crystal with heavy atoms such as samarium, iodine or gold. Anomalous dispersion is 
a powerful method as a single crystal is often enough to solve the structure and 
especially SeMet labeling can accelerate producing crystals containing suitable 
elements. The method does not require any prior knowledge about the structure of 
the measured protein and can thus be applied to every project, even if no suitable 
MR model is available and it avoids model bias. 
 
 
Fig. 13: The anomalous scattering factor contributions f´ and f´´ around an absorption edge. 
Red: theoretical curves; black: real values. The arrows mark wavelength commonly used for 
anomalous dispersion experiments. 1: The peak dataset contains the maximal anomalous differences 
(f´´ has its maximum value and f´ has a large negative value) and is thus usually the first dataset 
measured in a MAD experiment and the only one in a SAD experiment. 2: The inflection dataset 
carries the largest negative value for f´. 3: The high energy remote still has a high value for f´´, but 
nearly no f´. 4: The low energy remote carries no f´ and f´´ signal and is only of use in combination 
with the other datasets. (C) 2011 From Biomolecular Crystallography by Bernhard Rupp. Reproduced 
by permission of Garland Science/Taylor & Francis LLC. 
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Anomalous dispersion occurs near the absorption edges of elements within the 
crystals. The absorption of the X-rays leads to a small change (dispersive difference) 
in the intensity and phase of each reflection, described by the anomalous scattering 
factor contributions f´ and f´´, which are added to the structure factor of the 
anomalous scatterer (equation 4). These contributions are strongly wavelength 
dependent, f´ is minimal at the inflection point of the absorption edge, while f´´ is 
maximal at its peak (Fig. 13). 
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with f(S,λ) the atomic scattering factor of the heavy atom with anomalous scattering 
and f0(S) the scattering factor of the heavy atom without anomalous scattering. 
 
The most important consequence of this is the breakdown of Friedels Law. Friedels 
Law states that two structure factors Fhkl and F-h,-k,-l which are a so called Friedel pair 
are complex conjugates of each other, meaning that their magnitude is the same, but 
their phases are inverse. In the presence of anomalous scattering Fhkl and F-h,-k,-l 
have different magnitudes and also their phases are no longer related. These 
differences can be exploited to calculate the structure factors for the anomalous 
scatterers alone, which allows the determination of the “structure” of the anomalous 
scatterers by direct methods. This also provides phase information of the structure 
factors of the anomalous scatterers. By combination with the measured structure 
factors two possible phases for each protein structure factor can be calculated. As 
the scattering factors f´ and f´´ are dependent on the wavelength, measurement at a 
different wavelength provides the information necessary to determine the correct 
choice between the two phases (MAD). An alternative approach is to combine the 
two possible solutions into a best guess as to what the phase may be and use 
complementary methods such as density modification to improve this guess (SAD) 
(Fig. 14).  
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Fig. 14: Obtaining phase information from SAD data. Argand diagram of a protein structure factor 
(FP+) and its Friedel mate (FP-) (left panel) and the contribution of the anomalous scatterer FA. Only 
the anomalous components F´´A+ and F´´A- break Friedel`s Law, resulting in different vector sums FPA+ 
and FPA-. As the phase of these is not known we can represent them as circles with a radius of their 
structure factor magnitudes and their origin being shifted by their corresponding anomalous 
difference. These two circle intersect twice, giving two possible solutions for the phase. As it is 
unknown which of the solutions is the correct one, the average of both (FSAD) is used for phasing. (C) 
2011 From Biomolecular Crystallography by Bernhard Rupp. Reproduced by permission of Garland 
Science/Taylor & Francis LLC. 
 
3.2.5.5 Model building and refinement 
After initial phase information has been obtained the model of the protein can be built 
and by this the still erroneous phases can be improved. This is a cyclic process as 
improved phases lead to a better map which should allow for a more detailed model 
to be built. During this cyclic process two factors are of importance: the Rwork and 
Rfree. The Rwork is a measure of the quality of fit of the built model into the electron 
density. Its value should drop during refinement and it should reach a value of about 
15-25%, depending on the quality of the data. Yet, it is possible to fit the electron 
density with any atoms in a chemically not reasonable way to obtain very low Rwork 
values. To avoid this problem, called overfitting, the Rfree is introduced. It compares 
the structure factors generated by the model to a small subset of the data (usually 
5%) that has not been used for refinement and is thus independent. The Rfree is 
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always a few percent higher than the Rwork, but the gap between them should not 
exceed 7-8%. The quality of the model is also validated by checking various chemical 
parameters, such as the dihedral angles in the protein backbone (as presented in the 
Ramachandran plot), torsion angles and bond length.  
 
3.2.5.6 Refinement and validation 
For all proteins refinement was done with Refmac5 as included in the CCP4 suite. 
Waters were added manually and using the find water option in Coot. TLS groups for 
the proteins were determined by the TLS Motion Determination Server (Painter & 
Merritt 2006b) and a final round of TLS refinement (Painter & Merritt 2006a) in 
Refmac5 was carried out. The models were validated using the Ramachandran plot 
(Ramachandran & Sasisekharan 1968) and the torsion outliers tools in Coot as well 
as by Molprobity (Chen et al. 2010).  
 
3.2.6 Bioinformatics and tools 
Plasmids and primers were archived in VectorNTI, which was also used for virtual 
cloning. The Protparam tool (Gasteiger et al. 2003) was used to obtain theoretical 
data about the protein constructs such as extinction coefficients. Multiple sequence 
alignments were generated using ClustalW (Larkin et al. 2007) as incorporated in the 
T-coffee server (Notredame 2010) and figures of these were produced with ESpript 
(Gouet et al. 1999). Figures of the protein models were generated with pymol. The 
PISA server (Krissinel & Henrick 2007) was used to assess the relevance of the 
protein contacts in the crystal. All protein models were deposited in the Protein 
databank (PDB) (Berman et al. 2002). 
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4 Results 
4A Virulence regulation in pathogenic Yersinia 
 
4A.1 The transcription factor RovA 
4A.1.1 Purification of RovA 
The plasmid bearing the gene for RovA C81S, C108S (from now on simply termed 
RovA) was kindly provided by Boris Grujic (HZI, Braunschweig). Several mutants of 
RovA were generated by site directed mutagenesis and purified as described below 
for the wild type. The plasmid was transformed into BL21 cells and the protein was 
produced in M9 medium. After cell lysis RovA was purified from the supernatant via 
Ni-NTA affinity chromatography. The protein was eluted from the column using the 
elution buffer containing 250mM imidazole and the elution fractions were analyzed on 
an SDS gel (Fig. 15).  
 
 
Fig. 15: SDS gel of RovA Ni-NTA chromatography. M: Marker; S: soluble fraction; P: pellet; W1-3: 
wash; E1-3: elution fractions. 
 
A ThermoFluor assay revealed that RovA is most stable in buffers with high pH, thus 
a buffer with Tris/HCl pH 9 was used for gel filtration (Fig. 16). The protein eluted 
from the 16/60 SD200 column as a single peak at about 84ml. This corresponds to a 
molecular mass of about 40kDa. The calculated molecular mass of RovA is 17kDa 
and, thus, the calculated oligomeric state is 2.3, indicating a dimer as shown for other 
MarR type proteins (Hong et al. 2005). For further studies the protein was 
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concentrated to 50mg/ml and frozen in liquid nitrogen. The overall yield of pure RovA 
was about 15mg/L culture. 
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Fig. 16: RovA gel filtration. A: Chromatogram of gel filtration run. Absorption at 280nm is shown in 
blue, absorption at 260nm in red. B: SDS gel of eluted fractions.  
 
4A.1.2 Thermal stability 
RovA has been previously described as a protein thermometer that undergoes a 
conformational change upon increase in temperature leading to reduced DNA 
binding affinity and increased proteolytic degradation of RovA (Herbst et al. 2009). 
CD spectrum analysis suggested that RovA is a mostly α-helical protein. The 
conformational change upon temperature shift leads to a loss of α-helical and a gain 
of β-sheet content. These findings were investigated in more detail with RovA and 
several mutants. CD spectra of RovA were recorded in 3.3°C steps from 10°C to 
37°C (Fig. 17). The spectra remain relatively simil ar between 10°C and 20°C, 
whereas they change strongly with every interval afterwards. This indicates that the 
RovA structure remains the same at low temperatures and undergoes a 
conformational change at higher temperatures. It is however unclear whether all 
RovA molecules undergo a continuous change which increases upon temperature 
shift or whether there are only two distinct conformations and the population 
gradually shifts from one state to the other. Also the molecular mechanism of this 
conformational change remains elusive. Therefore, we aimed to find mutations in 
RovA which influence this thermosensing property.  
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Fig. 17: CD spectrum of RovA at different temperatures. 
 
4A.1.3 Binding of small compounds 
Many MarR-type transcription factors have been shown to bind small inducer 
molecules, most notably salicylate (Kumarevel et al. 2009; Providenti & Wyndham 
2001; Wilkinson & Grove 2004; Wilkinson & Grove 2006). Yet, for RovA no such 
inducer molecule has been reported. Thus, salicylate and several similar compounds 
have been tested by ThermoFluor assay for their capability to bind to RovA (Fig. 18). 
These experiments show that RovA is able to bind to salicylate with millimolar affinity. 
The addition of salicylate stabilises RovA by about 15°C. All related compounds such 
as benzoate and 4-hydroxybenzoate also bind RovA with comparable affinity, while 
derivatives with amino groups such as anthranilate and 4-aminobenzoate have 
slightly lower affinities and phenylalanine does not bind at all to RovA in the 
concentration range tested. Uric acid, which has been identified as a ligand for HucR 
(Wilkinson & Grove 2004), also does not bind to RovA. Interestingly, RovA showed a 
higher affinity for cinnamate and 3-chlorocinnamate than salicylate (about 1.8fold and 
4.3fold, respectively).  
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Compound KD [mM] 
Salicylate 2,25 
Benzoate 2,93 
2,3-Dihydroxybenzoate 2,33 
Anthranilate 3,92 
4-Hydroxybenzoate 2,75 
4-Aminobenzoate 5,86 
Cinnamate 1,27 
3-Chlorcinnamate 0,53 
Phenylpyruvate 3,52 
Phenylalanine no binding 
Uric Acid no binding 
 
 
 
Fig. 18: Affinity of RovA for small molecules. A: Plot of melting temperature against ligand 
concentration for RovA with salicylate (orange) and 3-chloro-cinnamate (green). B: List of dissociation 
constants for the tested molecules. C: Structures of tested molecules 
 
To test whether the binding of salicylate to RovA has any impact on the observed 
conformational change upon temperature change CD measurement with and without 
2mM salicylate were performed at 20°C and 37°C (Fig . 19). Unfortunately, salicylate 
absorbs light in the UV range and thus only 2mM salicylate could be used and even 
then the signal was only usable until about 215nm. Yet, even these truncated data 
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show that addition of salicylate stabilises the protein and seems to prevent the 
conformational change. 
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Fig. 19: CD spectra of RovA with and without 2mM salicylate at different temperatures. 
 
The impact of salicylate on DNA binding by RovA has also been tested by Frank 
Uliczka from the group of Prof. Petra Dersch, HZI. Gel shift assays were performed 
with varying concentrations of RovA in the presence and absence of 10mM salicylate 
with a fragment from the inv promoter region and, as a control, the csiD fragment 
from E. coli (Fig. 20A and B). These gels show that, while RovA alone binds to the 
inv promoter fragment with nanomolar affinity (a KD of 32nM has been reported 
(Herbst et al. 2009)), DNA binding seems to be severely impaired in the presence of 
salicylate. About twice as much RovA was needed compared to the gel without 
salicylate to observe a shift of the DNA. These results indicate that RovA is able to 
bind salicylate which stabilises RovA resulting in a reduced conformational flexibility 
and an increased melting point as well as decreases its DNA binding affinity. 
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Fig. 20: Gel shift assays of RovA and RovA P98S at 25°C and 37°C and in the presence and 
absence of 10mM salicylate. 
 
In order to determine the effect of salicylate-induced stabilisation in vivo, Y. 
pseudotuberculosis cells were grown in the presence of 1mM salicylate and the 
degradation of RovA with time was monitored by western blots. Preliminary results by 
Chriselle Mendonca as part of her PhD thesis indicate that salicylate is able to 
stabilize RovA in vivo (Fig. 21). Significantly more RovA was visible directly after 
blocking synthesis as well as later. Taken together, these results suggest that a small 
molecule such as salicylate might be involved in the regulation of RovA by stabilizing 
it. 
 
A B 
C D 
E F 
RESULTS  55 
 
Fig. 21: Stability assay of RovA in Y. pseudotuberculosis cells. YPIII cells were grown in the 
presence and absence of 1mM salicylate. Protein synthesis was stopped and the amount of RovA was 
monitored by a western blot. In the presence of salicylate significantly higher amounts of RovA can be 
seen in comparison to the absence of salicylate. 
 
4A.1.4 RovA P98S is more stable than the wild type in vivo 
A mutant of RovA (P98S) has been found by Frank Ulizcka in isolates of Y. 
enterocolitica serotype O:3 which showed an increased stability at 37°C in vivo 
compared to the wild type. Samples of Y. pseudotuberculosis YP3 and YP67 (a ∆lon 
mutant strain) complemented with a plasmid for the production of RovA and RovA 
P98S at 25°C and 37°C were analyzed on a western bl ot (Fig. 22). These blots 
indicate that RovA P98S is much more stable at 37°C  than the RovA WT. To test 
whether this effect is due to a difference in DNA binding, inducer binding, thermal or 
proteolytic stability gel shift assays with RovA P98S were performed at 25°C and 
37°C and in the presence or absence of salicylate ( Fig. 20C-F). These gels show that 
RovA P98S binds the inv promoter with similar affinity as the wild type and that the 
DNA binding is hampered by the addition of salicylate. Additionally, DNA binding 
affinity is also affected by increased temperature like the wild type.  
 
 
Fig. 22: Complementation assay of RovA WT and RovA P98S in YP3 and YP67 (∆lon) 
background. Samples from these strains producing the RovA variants at different temperatures were 
analysed on a western blot. 
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We further examined this mutant by thermofluor assays and CD spectroscopy. With 
the ThermoFluor experiment no difference in the melting temperature of PovA P98S 
compared to the wild type could be detected (35°C f or both; data not shown). The CD 
spectra showed that RovA P98S exhibits the same changes upon temperature shift 
as the wild type (Fig. 23). All these results together suggest that the mutation P98S in 
RovA does not influence the ability to bind DNA or salicylate nor influences the 
thermal stability of the protein. Therefore, we assume that this mutation has an 
influence on the proteolytic stability in vivo.  
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Fig. 23: CD spectra of RovA WT and RovA P98S.  
  
4A.1.5 RovA A10F, a stable mutant in vitro 
In order to interfere with the observed ligand binding, mutants of RovA (G6F and 
A10F) were produced in which small residues lining the proposed ligand binding 
pocket were replaced by the large amino acid phenylalanine. The stability and 
salicylate binding of these mutants were measured by ThermoFluor measurement 
(Fig. 24A). RovA G6F showed a similar melting temperature in the absence of 
salicylate as the wild type and was stabilised by the addition of salicylate like the wild 
type (Kd = 2mM and 2.4 mM for RovA G6F and the wild type, respectively). On the 
other hand, RovA A10F showed a significantly increased melting temperature in the 
absence of salicylate (TM = 53°C). RovA A10F is also stabilised by salicylat e, albeit to 
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a lesser extend than the wild type. The calculated dissociation constant for RovA 
A10F is 8mM, about 3 times higher than for the wild type.  
The mutants were also tested for their conformational flexibility by CD measurements 
at different temperatures. Again, RovA G6F shows spectra which are very similar to 
the wild type (data not shown), whereas RovA A10F showed a considerably reduced 
difference between the spectra recorded at 20°C and  37°C than the wild type (Fig. 
24B). These results suggest that the mutant RovA A10F is much more stable in vitro 
than the wild type and less able to bind salicylate. 
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Fig. 24: Stability and salicylate binding of RovA wild type and G6F and A10F mutants. A: The 
melting temperature was measured by a ThermoFluor experiment in the presence of increasing 
concentrations of salicylate and plotted against the salicylate concentration. B: CD spectra of RovA 
wild type and RovA A10F recorded at 20°C and 37°C.  
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4A.1.6 Crystallisation of RovA 
Crystallisation of RovA-apo was done by Boris Grujic as part of his PhD thesis 
(personal communication). RovA readily crystallizes in a variety of PEG containing 
conditions such as 0.1M MES pH 6.5, 25% PEG2000MME (Fig. 25A). Yet, even 
though the crystals can grow to a large size (up to 500µm) they do not diffract very 
well. Microseeding resulted in even larger crystals which were unfortunately not 
single crystals (Fig. 25B). For data collection the crystals were transferred into a cryo 
buffer containing 0.1M MES pH 6.5, 30% PEG2000MME and 10% glycerol and then 
frozen in liquid nitrogen.  
 
 
 
Fig. 25: Crystals of RovA apo. A: Non-seeded crystal B: Seeded crystals 
 
4A.1.7 Determination of DNA fragment for cocrystallization 
The success of protein/DNA cocrystallization is strongly dependent on the length and 
overhang of the DNA fragment (Tan et al. 2000) as the DNA fragments often 
assemble in a head to tail fashion to form a pseudo-continuous helix throughout the 
crystal. Therefore, the minimal DNA fragment still able to bind RovA efficiently was 
determined by gel shift assays. The smallest RovA binding fragment that had been 
determined previously from the inv promoter was the 29bp sequence 5`- 
taattgatattatttatatgataatagtt -3` (called 29; of the blunt end double stranded DNA, only 
one strand is shown here). From this smaller fragments were generated by deleting 
one base pair at each side of the fragment (leading to 27-11) and tested for RovA 
binding. The gels showed that the DNA binding capacity of the fragments decreased 
with the size of the fragment and that 21 was the shortest fragment that still bound 
RovA strongly (Fig. 26).  
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29: 5`- taattgatattatttatatgataatagtt - 3` 
27:  5`- aattgatattatttatatgataatagt - 3` 
25:    5`- attgatattatttatatgataatag - 3` 
23:     5`-  ttgatattatttatatgataata - 3` 
21:       5`- tgatattatttatatgataat - 3` 
19:        5`- gatattatttatatgataa - 3` 
17:          5`- atattatttatatgata - 3` 
15:            5`- tattatttatatgat - 3` 
13:             5`- attatttatatga - 3` 
11:              5`-  ttatttatatg - 3` 
Fig. 26: Gel shift assay of RovA with DNA fragments of varying size. +/- indicate the presence or 
absence of RovA. On the right one strand of the used fragments is shown, the complementary strand 
is left out for clarity. 
 
To test this fragment in more detail, new fragments were tested in which one 
basepair at only one side was deleted (Fig. 27). This experiment showed a 
preference of RovA for 3`-end truncations and thus 19b with the sequence 5`- 
tgatattatttatatgata - 3` was used as a minimal fragment. 
 
 
 
 
21:   5`- tgatattatttatatgataat - 3` 
20a:  5`- gatattatttatatgataat - 3` 
20b: 5`- tgatattatttatatgataa - 3` 
19a:   5`-  atattatttatatgataat - 3` 
19b: 5`- tgatattatttatatgata - 3` 
 
Fig. 27: Gel shift assay of RovA with DNA fragments of varying size. +/- indicate the presence or 
absence of RovA. On the right one strand of the used fragments is shown, the complementary strand 
is left out for clarity. 
 
4A.1.8 Crystallisation of RovA in complex with DNA 
From the determined minimal fragment 19b 5`- tgatattatttatatgata - 3` from the inv1 
site six different double stranded DNA fragments with different lengths and 
overhangs were devised. Fragments 20 and 21 were blunt end fragments, while 20A 
and 25A have an overhang for Watson-Crick base pairing. 20A allows the packing of 
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linear DNA, whereas 25A allows for bent DNA (Tan et al. 2000). Fragments 19C and 
19G were designed to allow Hoogstein base pairing. Yet, of these only 20A yielded 
crystals (see below). To obtain further insights into the DNA binding of RovA other 
fragments were designed in the fashion of 20A from two binding sites in the rovA 
promoter and from the second RovA binding site on the inv promoter (Table 8). Of 
these only Inv1 Art and rovA1A yielded crystals. 
 
Table 8: DNA fragments used for cocrystallization with RovA 
Name Sequence Overhang 
Inv1 20: 
 
FW: 5` - tgatattatttatatgataa - 3` 
RV: 3` - actataataaatatactatt - 5` 
Blunt end 
Inv1 21: 
 
FW: 5` - ttgatattatttatatgataa - 3` 
RV: 3` - aactataataaatatactatt - 5` 
Blunt end 
Inv1 20A:  
           
FW: 5` - atgatattatttatatgataa - 3`  
RV: 3` -  actataataaatatactattt - 5` 
 
5`A 
Inv1 25A:  FW: 5` - aaattgatattatttatatgataata - 3` 
RV: 3` -  ttaactataataaatatactattatt - 5` 
 
5`A 
Inv1 19C:  FW: 5` - cgatattatttatatgatc - 3` 
RV: 3` -  ctataataaatatactagc - 5` 
 
5`C 
Inv1 19G:  FW: 5` - ggatattatttatatgatc - 3` 
RV: 3` -  ctataataaatatactagg - 5` 
 
5`G 
Inv1 Art:  FW: 5` - atatgataaatgatattattt - 3` 
RV: 3` -atatactatttactataataa- 5` 
 
3`A 
Inv2a: 
 
FW: 5` - aatagactgttttattatata - 3` 
RV: 3` -  tatctgacaaaataatatatt- 5` 
 
5`A 
Inv2b: 
 
FW: 5` - aataaaacagtctataccata - 3` 
RV: 3` -  tattttgtcagatatggtatt - 5` 
 
5`A 
Rova1a: 
 
FW: 5` - aattatattatttgaattaat - 3` 
RV:  3` - taatataataaacttaattat- 5` 
 
5`A 
Rova1b: 
 
FW: 5` - tttacatccattaattatata - 3` 
RV: 3` -  aatgtaggtaattaatatatt - 5` 
 
5`A 
Rova2a: 
 
FW: 5` - tatgctagcacgctaattaaa - 3` 
RV:  3` - tacgatcgtgcgattaatttt- 5` 
 
5`A 
 
62  RESULTS 
RovA was crystallized in complex with DNA at a concentration of 20mg/ml protein 
and 8mg/ml DNA. Initial crystals appeared under the condition 0.05 M MES pH 5.6, 
0.01 M MgCl2, 2 M Li2SO4 (Fig. 28A). Optimisation of the crystallisation condition 
resulted in large, hexagonal crystals which strongly polarize the light, an indication for 
DNA, under the condition 0.05 M MES pH 5.6, 0.01 M MgCl2, 2.3 M Li2SO4 (Fig. 
28B). The crystals appeared after 1 week and grew to full size within 3 weeks. The 
crystals were transferred into a cryo buffer containing 0.05 M MES pH 5.6, 0.01 M 
MgCl2, 2.5 M Li2SO4 and 20% glycerol and then frozen in liquid nitrogen. 
 
 
 
Fig. 28: Crystals of RovA in complex with DNA. A: Initial crystals, B: Optimised crystals. 
 
4A.1.9 Crystallization of RovA with salicylate 
RovA was crystallized together with 50mM salicylate at a protein concentration of 
20mg/ml. Under several conditions, such as 0.1M MES pH 5, 2.4M ammonium 
sulfate, bundles of needles were observed (Fig. 29A). These crystals could be 
reproduced in 24-well hanging drop plates, yet, even with seeding it was not possible 
to obtain single crystals. Only by crystallization at 4°C, incubating for two days and 
then streak seeding under the condition 0.1M MES pH 5.6, 2 M ammonium sulfate, 
some single crystals could be obtained. Before freezing the crystals were transferred 
into a solution containing 0.1M MES pH 5.6, 2.5 M ammonium sulfate and 15% 
glycerol. 
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Fig. 29: Crystals of RovA with salicylate. A: Initial crystals; B: Optimised crystals 
 
4A.1.10 Data collection 
The RovA-apo crystals belong to the space group P212121 and a dataset up to 2.4 Å 
was collected at the ESRF ID14h2. The crystals of RovA in complex with DNA 
belong to the space group P3 and diffracted up to 1.85 Å, whereas the crystals of 
RovA in complex with salicylate belong to the space group C2 and diffracted up to 
2.4 Å The datasets were indexed with XDS (Kabsch, 2010) and scaled with Scala 
(Evans, 2006) as included in the CCP4 suite (CCP4, 1994). The Mathews coefficient 
for the RovA-apo data (Matthews, 1968) was determined to VM = 2.25 Å3 Da-1, 
indicating three RovA dimers in the unit cell. For the RovA-DNA crystals the Mathews 
coefficient (Matthews, 1968) was determined to VM = 3.33 Å3 Da-1, indicating a RovA 
dimer bound to one double-stranded DNA oligo in the unit cell, and VM = 1.99 Å3 Da-1 
for the salicylate containing crystals, indicating a RovA dimer in the unit cell. 
Molecular replacement was performed using MrBump (Keegan & Winn, 2007) 
employing Molrep (Murshudov et al., 1997) using SlyA from Salmonella typhimurium 
(accession code 3deu) as a model. However, molecular replacement for RovA-apo 
was only succesful using the structure of RovA in compex with the DNA. The protein 
models were built in Coot (Emsley et al., 2010) and refined using Refmac 
(Murshudov et al., 1997). Waters were added by the water finding tool in Coot as well 
as manually. In the end, a final refinement step using TLS refinement (Painter & 
Merritt, 2006a) with TLS groups as defined by the TLS Motion Determination Server 
(Painter & Merritt, 2006b) was carried out. In case of the DNA-complex crystals 
unambiguous density for the DNA was found. The DNA was modelled into the 
density and after refinement the Rwork and Rfree finally converged to 21% and 24% 
respectively. Rwork and Rfree for the RovA-apo structure converged to 22.8 and 
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28.4%, respectively. For the salicylate containing crystals, regions of electron density 
were found in four sites in the protein, which could be well described by salicylate. As 
the work on the RovA salicylate data could not be finished, the Rwork and Rfree 
were relatively high with 31.4% and 35.4%, respectively. This might be due to 
problems with crystal twinning.  
Table 9 and Table 10 summarize the data collection and refinement statistics. The 
final models were validated using MolProbity (Davis et al., 2007). For all models, all 
the residues fall into the allowed region of the Ramachandran plot (Ramachandran & 
Sasisekharan, 1968). 
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Table 9: RovA/ DNA data collection and refinement statistics 
 
 
 
RovA + inv1 RovA + rova1 
   
X-ray source 
 
ESRF ID14eh4 
 
ESRF ID14eh4 
 
Space group P3 P3 
Unit cell dimensions  
a, b, c (Å) 88.7, 88.7, 67.5 88. 8, 88.8, 67.7 
Wavelength (Å) 0.95 0.95 
Resolution (Å)* 76.8 – 1.85 37.1 – 2.1 
Measured 127340 (18753) 209176 (13305) 
Unique reflections* 49796 (7414) 39678 (5287) 
I/σI* 13.9 (2.5) 15.3 (2.0) 
Completeness (%)* 98.2 (99.9) 97.6 (89) 
Redundancy* 2.6 (2.5)  5.3 (2.5) 
Rmerge (%)* 3.4 (48.7) 5.8 (45.7) 
Wilson B factor (Å2) 33.74 38.8 
Solvent content (%) 69% 69% 
   
Rwork (%) 19.7 21.3 
Rfree (%) 23.1 25.2 
Protein atoms 2196 2162 
DNA atoms 855 855 
Solvent atoms 187 76 
r.m.s.d. from ideal 
geometry: 
  
-Bond lengths (Å) 0.011 0.022 
-Bond angles (°) 1.44 2.39 
Average B-factor   
-Protein (chain A) 17.1 23.5 
-Protein (chain B) 17.8 21.9 
-DNA (chain C) 33.1 43.6 
-DNA (chain D) 32.2 45.8 
-Solvent 20.6 19.6 
Ramachandran plot 
(%): 
  
-Favoured region 98.6 95 
-Allowed region 1.4 5 
 
* Values in parentheses refer to statistics in the highest resolution shell 
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4A.1.11 RovA/DNA crystal packing 
RovA was successfully crystallized in complex with a fragment of DNA from the inv 
promoter region (inv1) and another fragment from the rovA promoter (rovA1A). The 
structure was solved by molecular replacement using the homologue SlyA 
(accession code 3DEU), which shares a 75% sequence identity, as a model. The 
resulting map showed clear density for DNA as well as the loop between residue 80 
to 89, both of which were absent in the replacement model. In the space group P3 
there is one RovA dimer bound to one DNA fragment. In the crystal RovA is arranged 
layers where one dimer interacts with 4 other RovA dimers (Fig. 30). The RovA 
layers do not touch each other and crystal contacts between them are only mediated 
by the bound DNA which lies perpendicular to these planes. These DNA fragments 
bind to one another with their one basepair overhang in a head to tail fashion to yield 
a pseudo continuous DNA strand which spans the whole crystal. This crystal packing 
explains the high solvent content of 69%.  
 
 
Fig. 30: RovA/DNA crystal packing as viewed from above and from the side. RovA is organized 
in layers and interacts with four other dimers, whereas the layers are only connected by the DNA. 
 
4A.1.12 RovA structure in complex with DNA 
The structure of RovA overall resembles that of other MarR type proteins. It consists 
of six α-helices and two β-sheets with the topology: α1 (residues 5–23), α2 (residues 
30–42), α3 (residues 48–55), α4 (residues 60–72), β1 (residues 76–80), β2 (residues 
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88–92), α5 (residues 98–117) and α6 (residues 120–143) (Fig. 31A and B). From 
residue 94 to residue 97 as well as from residue 24 to 27 there are two one-turn 310-
helices. In several other MarR type proteins such as OhrR and MarR there is another 
β-sheet between α2 and α3, but in that region in RovA there are two prolines (P44 and 
P45) that probably prevent the formation of a β-sheet. The two monomers are tightly 
intertwined with the three long helices α1, α5 and α6, which form the dimer interface 
with a covered area of 2252.6 Å2 and a ∆G of -34.4 kcal/mol as calculated by the 
PISA server (Krissinel & Henrick 2007). The DNA binding domain is made up by the 
central part of RovA, namely helices α2-4, which form a helix-turn-helix (HTH) motif, 
and β1 and β2 which form a so called wing, to build an overall winged helix-turn-helix 
(wHTH) domain.   
 
Fig. 31: Structure of RovA. A: Cartoon representation of RovA in complex with DNA. One monomer 
is shown in blue, the other in blue-green, β-strands are shown in red and DNA in orange. B: Topology 
plot of RovA, showing domain organisation generated by Topdraw. 
 
4A.1.13 RovA-DNA interactions 
RovA was cocrystallized with DNA fragments from the inv (inv1) and rovA (rovA1A) 
promoter regions. Surprisingly, in the structure of RovA in complex with inv1 RovA 
does not bind in the middle of the DNA fragment, but rather on the edge of one 
fragment and also to the next fragment in the pseudo-continuous DNA helix (Fig. 
32A). Upon closer inspection of the new binding site sequence, it became evident 
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that, because of the pseudo-continuous DNA helix in the crystal, a binding site was 
generated, which is very similar to the original sequence (Fig. 32B). This new binding 
sequence (inv1new) contains about one half of one DNA fragment and about half of 
the neighboring fragment. Therefore, it seems that RovA has shifted its binding 
register by moving along the DNA during crystal assembly probably due to a higher 
affinity to the new sequence. That this preferential binding to the end of the DNA is 
not a crystal artifact is proven by the fact that RovA binds to the rovA1A DNA, which 
has been derived from the rovA promoter region, in the middle as expected (Fig. 
33A). Overall both structures are very similar with an rmsd between common Cα 
atoms of the structures of 0.41Å. 
RESULTS  69 
 
 
 
 
Fig. 32: Binding of inv1 by RovA. A: Cartoon representation of RovA in complex with inv1 DNA. One 
RovA dimer is shown in blue (chain A) and red (chain B), the DNA in green (chain C) and yellow 
(chain D) sticks. Two symmetry mates are shown in green. B: The sequence of the DNA fragments 
inv1 (chain C and D) are shown in black, the sequence of the next symmetry mates in the crystal are 
shown in green. Chain C was aligned with chain D (inv1new) to show the high similarity of the new 
binding site with the proposed binding site. Unmatched bases are marked by square boxes, orange 
circles mark the basepairs recognized by Q60. The dashes line is the middle of the pseudopalindromic 
sequence. C: Schematic drawing of the RovA inv1-DNA interactions. Direct interactions are 
symbolized by full arrows, water mediated interactions by dashed arrows. Bases are represented by 
rectangles, desoxyribose by pentagons, phosphates by circles. The colors of the RovA residues 
correspond to the chains as in A (blue: chain A, red: chain B). 
 
 
A 
B 
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Fig. 33: Binding of rovA1A by RovA. A: Cartoon representation of RovA in complex with inv1 DNA. 
One RovA dimer is shown in green (chain A) and brown (chain B), the DNA in green (chain C) and 
yellow (chain D) sticks. B: Structural alignment of RovA bound to inv1 (blue) and rovA1A (green). The 
role of Q60 is shown as it only binds to adenine. If there is a thymidine, as in rovA1A, the sidechain is 
disordered. The electron of the rovA1A structure is shown as grey mesh. C: Schematic drawing of the 
RovA rovA1A-DNA interactions. Direct interactions are symbolized by full arrows, water mediated 
interactions by dashed arrows. Bases are represented by rectangles, desoxyribose by pentagons, 
phosphates by circles. The colors of the RovA residues correspond to the chains (blue: chain A, red: 
chain B). 
 
RovA makes extensive interactions with the DNA in both structures (Fig. 32C and 
Fig. 33C). Helix α4 of the HTH motif is deeply inserted into the major groove of the 
DNA and makes most of the contacts to the DNA, but also helices α2 and α3 provide 
some contacts. The wing protrudes from the protein and reaches into the next minor 
groove thereby interacting with the DNA at several amino acid sites.  
B A 
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Most of these interactions, however, are not base specific. Instead, mainly the 
phosphate backbone of the DNA is contacted by hydrogen bonding with amino acids 
such as K88, Q49 and R78 (Fig. 34A) or backbone nitrogens (Fig. 34B).  
 
Only very few interactions are visible between RovA and the bases of the DNA. The 
most notable interaction is between Q60 and adenine residues at position 6 from the 
pseudosymmetric centre (Fig. 34D and Fig. 32C). This interaction might be the 
reason why RovA did not bind to the inv1 fragment in the middle as expected, as this 
arrangement would have allowed the binding of Q60 from only one monomer to the 
DNA, whilst the other would not have an adenine residue to bind to. The way inv1 
was found to be bound in the crystal allows both Q60 residues to bind to an adenine 
residue. Interestingly, in the structure with rovA1A only one Q60 is able to bind the 
DNA, while the other cannot because there is a thymidine instead of an adenine. For 
this glutamine residue no density is visible and it is thus probably disordered (Fig. 
33B).   
 
Another important residue is probably V64. This makes hydrophobic interactions with 
a thymidine residue at position 5 from the centre of pseudosymmetry in both 
monomers of both structures (Fig. 32C and Fig. 33C). Additionally, R86 contacts a 
thymidine residue while being held in place by D64 by hydrogen bonds (Fig. 34C). 
However, this interaction has been found only for one monomer of the RovA/inv1 
structure, while it was not found in the RovA/rovA1A structure even though there is a 
thymidine residue in the same position. This may be due to slight differences in the 
DNA due to the different gap positions. 
 
4A.1.14 A potential ligand cavity contains unexplained density  
A small cavity is present in the dimerisation domain of both monomers of RovA. This 
cavity is mostly lined with hydrophobic residues such as W16, W34, Y38 and I107 
(Fig. 34F). Inside this cavity, strong density was visible that could not be atributed to 
any of the substances from the crystallization buffer. It is therefore possible that a 
small molecule was bound to the protein from the expression host. The cavity has 
also been described for other MarR-type proteins suggesting a potential role as an 
inducer binding pocket (Wilkinson & Grove 2006). 
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Fig. 34: Critical RovA inv1-DNA interactions. RovA is shown in blue as cartoon and sticks. The 
DNA is shown as sticks; chain C is green, chain D is yellow. Density is shown at 1 sigma as grey 
mesh. A: Example of phosphate backbone binding by N49, K88 and R78 of RovA. B: The DNA 
phosphate backbone is also contacted by RovA backbone nitrogens and by water mediated 
interactions, here via K88, N49 and I50. C: Basespecific interaction between thymidin 12 and R86 
which is stabilized by D64. D: Basespecific interaction between adenine 15 and Q60. E: Hydrophobic 
interaction between V64 and thymidin 16 (yellow dots). F: Unexplained density within RovA, the FO-FC 
map is shown as green mesh at 4 sigma. 
A B 
C D 
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4A.1.15 The RovA-apo structure shows conformational flexibility 
By molecular replacement using the RovA/DNA structure five RovA monomers 
(chains A-E) were found in the asymmetric units. During model building, unassigned 
density for three long helices was discovered. These could be modelled and 
monomer A was used for replacing them by superposition. However, the electron 
density of this chain (F) remained weak in the parts now involved in dimer formation 
and therefore could be built partially. This is probably due to missing interactions in 
the crystal lattice. The wing of the DBD is disordered in all monomers of the RovA-
apo structure. It is probably very flexible and assumes a stable conformation only in 
the complex with the DNA. 
 
In total, six monomers were built, forming three dimers. All monomers share the 
same ovarall fold with rmsd values for common Cα atoms relative to chain A of 1.35 
Å/ 0.4 Å/ 1.1 Å/ 0.6 Å/ 0.6 Å for chains B/C/D/E and F, respectively. Those 
differences are mainly due to movements of the DBD (as for chain B) or the 
movement of one of the long helices (in chain D) (Fig. 35). The rmsd for common Cα 
atoms of the dimers CD/EF is 2.1 Å /2.0 Å compared to dimer AB. Therefore, the 
RovA-apo structure shows that the unliganded protein is relatively flexible, especially 
in the DBD. 
 
 
Fig. 35: Superpostion of the three RovA-apo dimers found in the asymmetric unit. The dimer 
AB is shown in blue, dimer CD in green and dimer EF in red. 
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Table 10: RovA apo and salicylate complex data collection and refinement statistics 
 RovA apo RovA + salicylate 
   
X-ray source 
 
ESRF ID14eh2 
CuKα Rigaku 
MicroMax 007HF 
Space group P212121 C2 
Unit cell dimensions  
a, b, c (Å) 
67.2, 74.8, 181.1 88.8, 88.8, 67.7 
Angles α, β, γ (°) 90, 90, 90 90, 95.6, 90 
Wavelength (Å) 0.933 1.54 
Resolution (Å)* 90.6 - 2.4 (2.46-2.4) 37.1 – 2.1 (2.2-2.1) 
Measured 217609 (16046) 54970 (6989) 
Unique reflections 36510 (2621) 15521 (2007) 
I/σI* 16.79 (2.9) 14.9 (3.8) 
Completeness (%) 99.8 (100) 98 (98.4) 
Redundancy 5.9 (6.1) 3.5 (3.5) 
Rmerge (%) 7.3 (68.0) 5.7 (44.5) 
Wilson B factor (Å2) 57.5 48.2 
Solvent content (%) 45 38.4 
   
Rwork (%) 22.8 31.4 
Rfree (%) 28.4 35.5 
Protein atoms 6245 1998 
Solvent atoms 98 73 
R.m.s.d. from ideal 
geometry: 
  
-Bond lengths (Å) 0.017 0.022 
-Bond angles (°) 1.71 2.19 
Average B-factor   
-Protein (chain A/B) 24.63, 22.7 30.1, 22.8 
-Protein (chain C/D) 33.7, 29.1 - 
-Protein (chain E/F) 26.3, 55.2 - 
-Solvent 29.5 32.5 
Ramachandran plot 
(%): 
  
-Favoured region 97.3 88.9 
-Allowed region 2.3 7.9 
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4A.1.16 The structure of RovA in complex with salicylate 
The structure of RovA in complex with salicylate could be solved by molecular 
replacement using the homologous structure from SlyA from S. typhimurium (pdb 
code 3DEU). Even though the structure could not yet be completed and the R factors 
are still quite high (probably due problems with twinning), the electron density 
allowed to build a model with good stereochemistry. Two monomers were found in 
the asymmetric unit, forming a dimer. Similar to the RovA-apo structure, the wing of 
the DBD was not visible in the structure. The two monomers align well with an rmsd 
for common Cα atoms of 0.7 Å. In every monomer two salicylate molecules (Sal1 and 
Sal2) were bound (Fig. 36A).  
 
Sal1 is bound in a pocket at the dimerisation interface between helices α1 and α5 of 
one monomer and α1 of the other monomer (Fig. 36B). This pocket is lined with 
hydrophobic residues such as W16, W34 and I107. The hydroxy-group of the 
salicylate molecule is bound by S7, while the negatively charged carboxyl group 
estiblishes hydrogen bonds to two arginine residues (R14 and R17). Therefore, this 
molecule is tightly bound within this pocket by hydrophobic and hydrophilic 
interactions. Sal2, however, is only weakly bound on the surface of the DBD (Fig. 
36C). It is only held in place by hydrophobic interactions with residues such as I56 
and I58 on a loop between helices α3 and α4. Thus, it is possible that the second 
salicylate molecule is only seen due to the unphysiologically high concentrations of 
salicylate (50mM) in the crystallization drop. However, the pocket of the first 
salicylate molecule is likely to be responsible for the ligand binding observed in vitro.  
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Fig. 36: Structure of RovA in complex with salicylate. A: Two salicylate (Sal1 and Sal2) molecules 
are bound to each RovA monomer. B: Sal1 is bound in a hydrophobic pocket. Electron density (2FO-
FC) is shown as grey mesh at 1 sigma. C: Sal2 is bound at the surface of the DBD of RovA 
 
A 
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RESULTS  77 
4A.2 The transcription regulator RovM 
4A.2.1 Purification of full-length RovM 
The purification and crystallization of RovM and RovM-EBD were performed by 
Marieke Dieckmann as part of her bachelor thesis. The plasmid for the production of 
full-length RovM, pAKH43, was kindly provided by the group of Petra Dersch (HZI, 
Braunschweig). The plasmid was transformed into E. coli BL21 cells and a 2L culture 
producing the protein was grown. After lysis of the cells the protein in the supernatant 
was purified by Ni-NTA affinity chromatography. The column was washed to remove 
unspecifically bound proteins and RovM was eluted by a buffer with a high imidazole 
concentration. The elution fractions were tested on an SDS gel for purity and protein 
yield (Fig. 37).  
 
 
Fig. 37: SDS-gel of full-length RovM fractions after Ni-NTA purification. M: Marker, 1: pellet, 2: 
supernatant, 3: flow through, 4-6 waash, 7-10: elution.  
 
To find a suitable buffer for gel filtration a ThermoFluor screen was performed. The 
screen showed that RovM was most stable at buffers with high pH and salt. Thus, 
20mM Tris/HCl pH8, 100mM NaCl and 5mM DTT was chosen for gel filtration. The 
protein was concentrated to 1ml and applied to a 16/60 SD200 gel filtration column. 
The protein eluted as a single peak at 87ml (Fig. 38). This corresponds to a 
molecular mass of 174.9kDa while the calculated molecular mass of a monomer is 
37kDa. Thus, the calculated oligomeric state of the protein is 4.7, indicating a 
tetramer in solution which has been observed for several other LTTR proteins as well 
(Muraoka et al. 2003).  
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Fig. 38: Gel filtration of full-length RovM. A: Chromatogram of gel filtration run. Absorption at 
280nm is shown in blue, absorption at 260nm in red. B: SDS gel of eluted fractions. M: Marker, 1: first 
small peak, 2-7 large peak.  
 
4A.2.2 Design of the RovM-EBD construct 
The domain boundary of the effector binding domain of RovM (RovM-EBD) was 
determined by comparison with structures and sequences of other LTTR proteins. 
The construct containing amino acids 92-310 was amplified from the plasmid 
pAKH43 which was used for the production of full-length RovM. The insert had the 
same restriction sites (NdeI and XhoI) as were used for the generation of pAKH43 
and was cloned into the same plasmid.  
 
4A.2.3 Purification of RovM-EBD 
The protein RovM-EBD was produced and purified similar to the full-length protein. It 
was produced in BL21 cells, purified using Ni-NTA affinity chromatography and 
elution frations were analysed by SDS PAGE (Fig. 39).  
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Fig. 39: SDS gel of RovM-EBD Ni-NTA chromatography. M = Marker, 1 = pellet, 2 = flow through, 
3 – 5 = wash, 6 – 8 = elution fractions. 
 
As a final purification step, gel filtration with the same buffer as for full-length RovM 
was done (Fig. 40). The protein eluted at 80 ml, which corresponds to a molecular 
mass of 57 kDa. With a calculated molecular mass of 26 kDa this results in an 
oligomeric state of 2.2, indicating a dimer in solution. This agrees with previous 
results that EBDs are dimers in solution (Ezezika et al. 2007). 
 
 
 
Fig. 40: Gel filtration of RovM-EBD. A: Chromatogram of gel filtration run. Absorption at 280nm is 
shown in blue, absorption at 260nm in red. B: SDS gel of eluted fractions. M: Marker, 1: first small 
peak, 2-9 large peak.  
 
4A.2.4 Crystallization of full-length RovM and RovM-EBD 
To find initial crystallization conditions, several commercially available crystallization 
screens of full-length RovM and RovM-EBD were set up. Despite extensive 
screening, no crystals of full-length RovM could be obtained. RovM-EBD on the other 
hand crystallized under several conditions with a pH of about 7 and higher molecular 
mass PEG (Fig. 41).  
RovM-EBD 
26kDa 
RovM-
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Fig. 41: Initial RovM-EBD crystals. A: 0,1 M KCl; 0,1 M HEPES pH 7,0; 15 % PEG 6000 B: 0,1 M 
HEPES pH 7,5; 20 % PEG 8000. C: Crystals stained with methyleneblue (Izit). 
 
Optimization of the crystallization conditions to 0.1 M HEPES pH 8.0 and 12.5 % 
PEG 6000 yielded large crystals that grew within 3 weeks (Fig. 42). To obtain 
phases, RovM-EBD crystals were soaked with 50mM SmCl3 for 10min or 400mM 
magic triangle, both in reservoir solution. Before measurement the crystals were 
transferred into a drop with 0.1 M HEPES pH 8.0, 25 % PEG 6000 and 10% glycerol 
for cryo protection and then flash frozen. 
 
  
Fig. 42: Optimised RovM-EBD crystals used for data collection. 0.1 M HEPES pH 7.5 (A) or pH 
8.0 (B) and 12.5 % PEG 6000. 
 
4A.2.5 Data collection 
The RovM-EBD crystals belonged to the tetragonal space group I4122 with unit cell 
parameters a=b= 69.47 Å and c=351.22 Å. Calculation of the Matthews coefficient to 
VM = 2.12 Å3 Da-1 indicated two monomers per asymmetric unit corresponding to a 
solvent content of 43%. To solve the phase problem, molecular replacement was 
tried using several EBD structures (1AL3 (CysB), 2FYI (Cbl), 2H98 (CatM) and 2H9B 
(BenM)) as well as parts of these, but no solution could be obtained. Therefore, the 
crystals soaked with SmCl3 and magic triangle were measured at the home-source at 
C 
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1.54 Å. This is not the peak wavelength for samarium (L-I edge: 1.60 Å) or iodine (L-I 
edge: 2.39 Å), as incorporated in the magic triangle, but rather a high remote, yet, 
sufficient high anomalous signal was obtainable (Fig. 43). In particular, the Sm L-I 
edge was quite close giving a strong signal with a calculated f´´ of 12.2e and an f´ of -
5.5e.  
 
 
Fig. 43: Plot of the anomalous scattering contributions f´ and f´´ for samarium. f´´ is shown as a 
thick line, while f´´ is shown as the thin line. The absorption edges and the Cu Kα wavelegh are 
marked. Generated by the edge plot tool from http://skuld.bmsc.washington.edu/scatter/AS_form.html. 
(Evans & Pettifer 2001) 
 
Substructure solution with ShelX (Sheldrick 2008) was successful for both derivatives 
finding 3 iodine sites in the magic triangle derivative (corresponding to one magic 
triangle molecule) and for the Sm derivative 4 strong and several weak sites were 
found. Yet, the one bound magic triangle molecule did not generate enough phasing 
power to obtain useful phases. The Sm derivative on the other hand provided useful 
phases after refinement of the heavy atom positions by Phaser (McCoy et al. 2007) 
and density modification by Parrot (Cowtan 2010). A first model was built by 
Buccaneer (Cowtan 2006) and then refined manually in Coot (Emsley et al. 2010) 
and with Refmac5 (Murshudov et al. 1997). After several rounds of refinement and a 
last TLS refinement step, Rwork and Rfree reached 22.1% and 29.5%, respectively. 
The rather large difference between these two values probably results from the bad 
electron density for some parts of the B chain. The final model was validated by 
Molprobity (Chen et al. 2010) and the Ramachandran plot showed 97.8% of the 
residues in the favoured region and 2.2% in the allowed region. 
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Table 11: RovM-EBD data collection and refinement statistics 
 SAD native 
X-ray source 
 
 
CuKα Rigaku 
MicroMax 007HF 
ESRF ID 29 
 
Space group I4122 I4122 
Unit cell dimensions  
a, b, c (Å) 
69.03, 69.03, 352.49 69.47, 69.47, 351.22 
Wavelength (Å) 1.54 0.97 
Resolution (Å)* 
 
88.6-2.5 
 
87.8-2.4 (2.53 - 2.4) 
Measured reflections* 192810 (23819) 182593 (22862) 
Unique reflections* 26240 (4108) 17557 (2485) 
I/σI* 28.7 (4.9) 16.4 (3.5) 
Completeness (%)* 99.4 (96.7) 99.9 (100) 
Redundancy* 7.3 (5.8)  10.4 (9.2) 
Rmerge (%)* 6.3 (41.6) 7.4 (54.0) 
Wilson B factor (Å2) 33.75 59.3 
Solvent content (%) 43% 43% 
   
Rwork (%)  22.1 (23.4) 
Rfree (%)  29.5 (30.2) 
Protein atoms  2142 
Solvent atoms  142 
r.m.s.d. from ideal geometry:   
Bond lengths (Å)  0.014 
Bond angles (°)  1.575 
Average B-factor (Å2):   
Protein (chain A)  56.4 
Protein (chain B)  62.7 
Solvent  55.3 
Ramachandran plot (%):   
Favoured region  97.8 
Allowed region  2.2 
 
4A.2.6 Crystal structure of RovM-EBD 
The structure of RovM-EBD consists of two distinct domains EBDI and EBDII, which 
are connected by two crossovers at the two β-strands β4 and β10. EBDI is 
composed of a 5 stranded β-sheet and 3 α-helices around the sheet, while EBDII 
consists of a strongly twisted 5 stranded β-sheet with four α-helices around it (Fig. 
44A and B). The asymmetric unit contains two chains of RovM-EBD. These adopt the 
same fold, yet, due to crystal packing, show slight differences (Fig. 44C). For chain A 
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all residues from 99 to 289 could be modeled except for residue 159, whereas for 
chain B only residues 100 to 280 with a gap at residue 128 were built. Most of the 
differences are in the EBDI while the EBDII is nearly identical. For example, the C-
terminal α-helix is well resolved in chain A while the density was much worse in chain 
B, where it is missing some crystal contacts. These differences are signified by the 
r.m.s.d. of 0.91 Å for all common Cα atoms.  
 
 
 
 
Fig. 44: Structure of RovM-EBD monomer. A: Cartoon representation showing the two distinct 
domains and the possible ligand binding site; B: topology plot, generated by Topdraw (Bond 2003); C: 
Superposition of chain A and B. Chain A is shown in blue, chain B in red. 
 
4A.2.7 Oligomeric state of RovM-EBD 
Full length LTTRs can exist in several oligomeric states, ranging from dimers over 
tetramers to octamers (Monferrer et al. 2010). The gel filtration analysis of full length 
RovM indicated a tetrameric assembly, similar to CbnR (Muraoka et al. 2003). EBDs 
on the other hand have been reported to be dimers in solution (Ezezika et al. 2007). 
The gel filtration analysis of RovM-EBD indicates that RovM-EBD is also a dimer in 
solution. As a matter of fact, in the asymmetric unit there are two monomers present 
which share a quite large interface of 845.7 Å2 (Fig. 45). This interaction is mostly 
mediated by helix 1, sheet 4 and sheet 9 as well as the loop preceeding sheet 9. Yet, 
comparison with structures of other LTTR EBDs showed that this interface is different 
from the usual dimer interface. Thus, the crystal contacts with the symmetry mates of 
RovM-EBD were evaluated using the PISA server and it became apparent, that 
RovM-EBD shows several different significant interfaces within the crystal packing. 
A B C 
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The strongest of these is the interface between chain B and its symmetry mate B´ 
(Fig. 45). This interface is the same as the typical EBD dimer interface, where the 
two monomers are arranged in a head-to-tail fashion with the EBD-I of one molecule 
interacting via helix 1 with the helix 4 of the EBD-II of the other molecule covering 
interface area of 883.8 Å2. Yet, the interface between A and its symmetry mate A` is 
different (Fig. 45). The two monomers are shifted relative to each other and thus the 
interaction is mediated by helices 1 and 4 and sheet 2. Even though the interface 
area is, with 945.6 Å2, larger than the other interfaces, it is less stable and was 
considered to be less relevant by the PISA server. From these data we conclude that 
RovM-EBD probably is a dimer in solution characterised by the BB´ interface, while 
the strong interaction between chain A and B in the crystal leads to a distortion of the 
AA` interface. Another weak interface was observed between two A or B chains 
(termed AA`` or BB``) (Fig. 45). This interaction covers an area of 681.8 Å2 and 642.7 
Å2 for AA`` and BB``, respectively and is mediated by helices 2 and 3.  
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Fig. 45: Structures of the interfaces between RovM-EBD monomers in the crystal. Chain A is 
shown in blue, chain B in red. The AB interface is seen in the asymmetric unit. The BB` interface is 
seen in all structures of LTTRs and is thus termed the physiological dimer. The AA` interface is similar 
to the BB` interface but the two EBDs are shifted relative to each other. The AA`` interface (and the 
BB`` interface, not enlarged) is seen in some other LTTRs and seems to mediate tetramer formation. 
 
4A.2.8 Ligand binding pocket 
Small molecules, called inducers, that bind to LTTR proteins have been shown to 
play an important role in gene regulation (Schell 1993). Often these molecules are 
related to the genes they influence, such as benzoate in aromatic compound 
degradation (Ezezika et al. 2007). They usually bind in a cavity between the two 
domains (EBDI and EBDII) of the EBD, which is thought to result in a conformational 
change in the EBD. This is translated via the long lever-like linker helix into a 
repositioning of the DBD and a resulting relieved bending of the DNA (Schell 1993). 
So far, no inducer is known for RovM, but the EBD structure has a cavity (roughly 
10.5 Å wide, 7.1 Å high and 6.5 Å deep) in the interface between the two domains 
that is of a suitable size to bind a small ligand. The cavity is lined with two 
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hydrophobic residues (Y198 and L222) and several hydrophilic residues (D106, 
D107, S137, T155 and R238), suggesting that a rather hydrophilic inducer molecule 
could bind in this cavity. 
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4B Polyketide synthases 
 
4B.1 The octenoyl-CoA carboxylase/reductase CinF 
4B.1.1 Purification of CinF 
The cinF gene from S. coelicolor was cloned and the protein produced with an N- 
terminal SUMO-tag in the group of Rolf Müller (Saarland University, Saarbrücken). 
The protein was purified by affinity chromatography and the tag was cleaved off (Fig. 
46). Then the protein was kindly provided for further experiments.  
 
 
 
Fig. 46: SDS gels of CinF (kindly provided by Rashid Shwan, Saarland University, 
Saarbrücken). A: M: marker; S: soluble lysate; W1-4: wash; E1-4: elution fractions. B: CinF before 
and after cleavage of the SUMO tag. 
 
First, a ThermoFluor screen was performed to find a buffer in which the protein was 
stable. The screen showed that CinF is most stable at higher pH values and thus 
10mM Tris pH 8 and 100mM NaCl was used as buffer for CinF. Subsequently, the 
protein was further purified by gel filtration on a 16/60 gel filtration column using the 
gel filtration buffer (Fig. 47A). The elution fractions were analysed by SDS PAGE and 
pure fractions were pooled and concentrated for crystallization (Fig. 47B). 
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Fig. 47: Gel filtration of CinF. A: Elution profile. Absorption at 280nm is shown in blue, absorption 
at 260nm in red. B: SDS gel of eluted fractions. M: Marker, 1-6 large peak (elution volume 62-72ml). 
 
4B.1.2 Crystallization of CinF 
Initial screening for crystallization conditions yielded small plate-like crystals under 
the condition: 0.1M CHES pH 9.5 and 10% PEG3000 (Fig. 48A and B). These could 
only be reproduced by streak seeding from the initial crystals into fresh crystallization 
drops. After optimization of the crystallization conditions in 24 well plates, larger 
crystals were obtained that were still very thin and fragile and did not diffract very 
well. Seeding from these into the drops of the initial screens that had remained clear 
yielded several new crystallization conditions. Of these, 0.1M Tris pH 7, 20% glycerol 
and 12% PEG8000 produced thicker crystals and was already a cryo solution 
reducing damage to the fragile crystals by handling. The protein was crystallized in 
drops containing 1µl protein and 1µl reservoir buffer that were incubated for one day 
and then streak seeded from older crystals. Large crystals grew within one day and 
reached their final size within 3 days (Fig. 48C). Crystals containing NADP+ and 
octenoyl-CoA were produced by adding 10mM NADP and 10mM octenoyl-CoA to the 
protein solution before crystallization.  
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Fig. 48: CinF crystals. A: Initial crystal in 0.1M CHES pH 9.5 and 10% PEG3000; B: Initial crystals 
stained with methyleneblue (Izit); C: Optimized crystals in 0.1M Tris pH 7, 20% glycerol and 12% 
PEG8000 
 
4B.1.3 Data collection 
A native CinF dataset was measured at ESRF (Grenoble, France) beamline ID 29, 
equipped with an ADSC Q315R detector. A Micromax-007 HF rotating copper anode 
X-ray generator (Rigaku) with a Saturn 944+ CCD detector (Rigaku) was used to 
measure the data set of CinF with NADP and octenoyl-CoA diffracting to 1.9 Å. The 
CinF crystals belong to the space group P21 with unit cell dimensions a= 96.01 Å, b= 
83.30 Å and c= 122.74 Å and α=γ= 90° and β= 110.96°. The data processing was 
carried out using XDS (Kabsch 2010) and scaling was done with XSCALE. The 
Matthews coefficient (Matthews 1968) of VM = 2.39 Å3 Da-1 indicated four monomers 
per asymmetric unit corresponding to a solvent content of 48%. To obtain initial 
phases molecular replacement by MOLREP (Murshudov et al. 1997) was perfomed 
using the putative crotonyl-CoA carboxylase/reductase (3KRT) as a search model, 
finding four monomers in the asymmetric unit. The structure was refined with 
REFMAC5 (Murshudov et al. 1997) and completed in Coot (Emsley et al. 2010). For 
the data set of CinF in complex with its substrates the model of the apo-structure was 
used for molecular replacement. Clear density for NADP was visible in all monomers 
and also for octenoyl-CoA in two monomers, whereas in the other two monomers the 
density was much weaker. Structure and restraint files for octenoyl-CoA were 
generated using the Dundee Prodrg server (Schuttelkopf & van Aalten 2004). The 
octenoyl-CoA was build into the monomer with the best density (chain A) and, by 
applying the symmetry, placed in the other monomers as well. Water molecules were 
added manually and using the water find tool in Coot. A final TLS refinement (Painter 
& Merritt 2006a) step using five TLS groups per monomer as determined by the TLS 
A B C 
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Motion Determination Server (Painter & Merritt 2006b) was carried out with 
REFMAC5. The final R values were 21.8 / 27.6 % (Rwork / Rfree) for the apo-form 
and 19.9 / 24.6 % for the ligand bound form, respectively. 
 
In Table 12 data collection and refinement statistics are listed. MolProbity (Chen et 
al. 2010; Davis et al. 2007) validation indicated a good quality model. Nearly all 
residues fall within the allowed regions of the Ramachandran plot (Ramachandran & 
Sasisekharan 1968). Only in the complex structure H313, which is involved in 
substrate binding, is an outlier in all chains. The relevance of the crystal contacts was 
assessed using the PISA server (Krissinel & Henrick 2007). 
 
4B.1.4 CinF structure 
In this work we present the structure of the octenoyl-CoA carboxylase/reductase 
CinF in its apo-form at 2.0 Å resolution as well as in complex with its ligands NADP 
and octenoyl-CoA at 1.9 Å resolution. The asymmetric unit contains four CinF 
monomers (chain A-D) (Fig. 49A). The apo structure had weak electron density in 
some parts, probably due to flexibility in the absence of the ligands. The residues 1-
347 were modelled for chains A and B with gaps between residues 275-286 and 335-
347 and residues 1-352 were built for chains C and D with gaps between 275-286, 
313-317 and 335-347. These parts were well defined in the structure with NADP and 
octenoyl-CoA, which comprises the residues 1-445. Apart from the sections missing 
in the apo-structure, both structures align quite well with an average rmsd of 0.63 for 
shared Cα atoms for each chain. Thus, unless otherwise stated, it is referred to the 
structure of the complex in the rest of the text.  
 
The monomers superimpose very well upon each other with an rmsd of 0.13 Å 
between chain A and chain B as well as 0.25 Å and 0.21 Å between chain A and 
chain C or chain D, respectively. Each CinF monomer can be divided into two 
domains: the N-terminal catalytic domain (residues 1-201 and 361-445), which is 
necessary for substrate binding and catalysis, and the C-terminal cofactor binding 
domain (residues 202-360), which binds NADP(H) (Fig. 49B). The cofactor binding 
domain exhibits a Rossmann fold, containing two mononucleotide binding βαβαβ 
motifs and an additional strand β14 (Fig. 49C). The catalytic domain consists of a 
seven stranded antiparallel β-sheet, a separate three stranded antiparallel β-sheet 
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and 11 α-helices. The long α-helix α9, which connects both domains, is considered to 
be part of both domains as the N-terminal part of the helix is involved in substrate 
binding, whereas the C-terminal part is involved in NADP(H) binding.  
 
Table 12: CinF data collection and refinement statistics 
 
 
apo octenoyl-CoA/NADP 
complex 
Beamline 
 
ESRF ID 29 
 
CuKα Rigaku 
MicroMax 007HF 
Space group P21 P21 
Unit cell dimensions a, b, c (Å) 101.64, 85.22, 113.97 96.01, 83.32, 122.74 
α,β,γ (°) 90, 107.4, 90 90, 110.9, 90 
Wavelength (Å) 0.976 1.54 
Resolution (Å) 48.48-2.1 (2.25-2.1) 47.2-1.9 (2.0-1.9) 
Measured reflections 357025 (63670) 505455 (61327) 
Unique reflections 107076 (19855) 140724 (18977) 
I/σI* 8.78 (3.68) 13.85 (3.6) 
Completeness (%) 98.76 (98.83) 98.8 (94.1) 
Redundancy 3.3 (3.2) 3.6 (3.2) 
Rmerge (%) 15.8 (62.2) 8.7 (42.6) 
Wilson B factor (Å2) 30.8 27.0 
Solvent content (%) 48 48 
   
Rwork (%) 21.78 19.94 
Rfree (%) 27.65 24.65 
Protein Atoms 12550 13389 
Ligand Atoms - 400 
Solvent Atoms 1515 1905 
r.m.s.d. from ideal geometry   
Bond lengths (Å) 0.0132 0.0106 
Bond angles (°) 1.52 1.61 
Average B-factor (Å2)   
Protein (chains A, B, C,D) 5.66, 6.37, 9.45, 6.95 3.43, 4.29, 4.09, 4.87 
NADP  - 15.3, 16.4, 25.2, 22.8 
Oct-CoA  - 33.6, 39.1, 75.9, 55.78 
Solvent 18.37 14.2 
Ramachandran plot (%)   
favoured 95. 8 96.0 
allowed 3.6 3.9 
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Fig. 49: Structure of CinF. A: Quarternary structure of CinF showing the dimer of dimers fold. The monomers are shown as cartoon and transparent surface 
in green, blue, yellow and red. The ligands are shown as sticks. B: Cartoon representation of CinF monomer. Helices are colored in blue, β-sheets in red and 
loops in white. The ligands are shown as sticks, the NADP+ is green, the octenoyl-CoA yellow. C: Topology plot of CinF, showing the domain organisation and 
the secondary structure of CinF drawn with Topdraw (Bond 2003). 
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4B.1.5 Oligomerisation 
In the asymmetric unit four CinF monomers were found in a tetrameric dimer of 
dimers assembly (Fig. 49A). Size exclusion chromatography of CinF suggests a 
molecular mass of 176 kDa (the calculated molecular mass of CinF is 48kDa) 
corresponding to a calculated oligomeric state of 3.7. Analysis of the most probable 
assembly using the PISA server also suggests a tetramer covering an area of 25,410 
Å2. The strongest interaction between two monomers is between the cofactor binding 
domains of chains A and D as well as chain B and C with an average interface area 
of 1475 Å2 forming two dimers. This interaction is mainly mediated by β15 of both 
subunits, thus creating a continuous 12 stranded β-sheet, β14, interacting with the 
same β-strand from the other chain, and helix α16, which is inserted between the two 
domains of the other chain. Interestingly, β14 and the preceding loop are disordered 
in the apo-structure, probably due to the lack of stabilisation by the ligands. The two 
dimers interact via two interfaces to form the tetramer. The first tetramer interface is 
between the catalytic domains of chain A and B and chain C and D covering an 
average area of 1252 Å2. Here helix α8 of one chain is wedged between the helices 
α8 and α17 of the other chain. The second tetramer interface is relatively weak 
covering an area of only 629 Å2. It is mediated by loop regions between α9 and β9 as 
well as between α10 and β9 in the cofactor binding domain of chains A and C and 
chains B and D. 
 
4B.1.6 NADP+ binding 
Between the two domains of CinF there was a strong density allowing unambiguous 
placement of the NADP+ molecule in all four subunits (Fig. 50A). The NADP+ 
molecule assumes an extended conformation and is only slightly bent around two 
loops of the protein, the loop preceding β14 and the loop between β12 and α15. 
These loops make several interactions with the NADP+ molecule and are disordered 
in the apo-structure. The NADP+ molecule is tightly bound to the protein via many 
hydrogen bonds and hydrophobic interactions. The adenine group is bound mostly 
via water mediated contacts and hydrophobic interactions with serine residues 338 
and 339. The specificity of reductases for NAD(H) or NADP(H) is determined by the 
residues that bind to the 2`phosphate group of NADP(H) or prevent the placement of 
the phosphate group. In the CinF structure the 2`phosphate group is recognized by 
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hydrogen bonds with Lys257 and with the OH group and the backbone nitrogen of 
Ser253 as well as several water mediated interactions with e.g. Arg272 and Ser230. 
This shows that NADP(H) is indeed the cofactor and not NAD(H). The pyrophosphate 
group is tightly bound via hydrogen bonds with Gln405 and the backbone nitrogens 
of Gly232 and Leu233 as well as several water mediated interactions. The last two 
residues are located at the N-terminal end of helix α10, so that the positive dipole of 
the helix can compensate the negative charge of the phosphates  These residues are 
part of a GXXGXXG motif, which has been shown to be the cofactor binding motif in 
quinone oxidorectuctases, with which CinF shares some homology (Edwards et al. 
1996). The nicotinamide group, which assumes an anti-conformation, on the other 
hand is inserted in a hydrophobic pocket lined by Leu201, Thr205, Leu233 and 
Cys335. Only the amide group is held in position by hydrogen bonds with Thr205 and 
His361.  
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Fig. 50: Ligand binding by CinF.  CinF is shown as cartoon and sticks, chain A is colored blue and 
chain D yellow. NADP+ and Octenoyl-CoA are shown as green and pink sticks, respectively. The 
electron density is shown at 1.0 sigma as grey mesh. A: Interactions between NADP+ and CinF 
showing the residues responsible for cofactor specificity. B: Stereo image of the hydrophobic substrate 
binding pocket for the octenoyl-chain. C: Stereo image of the binding of the CoA at the interface 
between chain A and D.  
 
A 
B 
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4B.1.7 Octenoyl-CoA binding 
Good density for the octenoyl-CoA in the monomers A and B, whereas the density 
was poorer in monomers C and D, suggesting only partial occupancy of the ligand. 
Octenoyl-CoA was built into the monomer with the best density (A) and then placed 
in the other monomers by using the non-crystallographic symmetry. The binding of 
octenoyl-CoA is described here for chain A. The long and flexible ligand is bound in 
an extended conformation, in which the acyl-group is buried within the catalytic 
domain while the CoA is bound on the surface of the monomer and held in place by 
interactions with the dimer partner (chain D) of chain A (Fig. 50B). The acyl-group is 
accommodated by a hydrophobic pocket created by residues Pro141, Ala142, 
Met156, Ala163, Leu201, His361 and Gly362 as well as the nicotinamide group of 
the NADP+ molecule. This places the C3 of the octenoyl-chain in a perfect position 
for the hydride transfer from an NADPH molecule.  
 
The pantethein part of the CoA is bound in the interface between the catalytic domain 
of chain A and α14 and α16 of chain D (Fig. 50C). It is mostly contacted by 
hydrophobic interactions with Trp80, Pro86, Leu87, Phe92 and Phe166 from chain A 
as well as Tyr349 and Met352 from chain D. Additionally, there is a hydrogen bond 
from Arg348 and some water mediated interactions. The rest of the CoA molecule 
winds around helix α6 and the preceding loop. The phosphates of the CoA molecule 
are contacted by His91 from chain A and Arg286, Arg293 from α14 and Tyr349 from 
α16 of chain D. These residues are not visible in the apo-structure and are probably 
flexible without a ligand bound.  
 
The ribose and the adenine parts of the CoA molecule on the other hand are 
positioned on the surface of monomer A. They are only held in place by hydrophobic 
interactions with Leu87, Pro88 and His91 and a water bridge to Asp36.  
 
4B.1.8 CO2 binding 
It has been shown that CCRs use CO2 to carboxylate their substrate from the re face, 
in an anti position to the hydride transfer (Erb et al. 2009). We aimed to confirm this 
by solving the structure of CinF in complex with CO2. However, cocrystallization with 
as much as 100mM Na2CO3 or CS2 as a CO2 mimic yielded no visible density for CO2 
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(or CS2) in the structure. Thus, we tried to aerate the crystals with up to 40bar CO2 in 
a pressure chamber for 15min directly before freezing, yet even this measure was 
unsuccesful. Probably, the affinity for CO2 is low and it is thus not visible in the 
structure. Therefore, we docked the CO2 molecule into the structure in silico by 
GOLD (Verdonk et al. 2005). Several very similar solutions were found, all of them 
with a relatively low affinity (Fig. 51). The CO2 molecule is held in place by hydrogen 
bonds with residues N77 and E167 as well as hydrophobic interactions with the 
underlying F166. It is in an anti position relative to the NADP and the distance is 
about 3.3Å from the C-atom of the CO2 to the C2. Therefore, we deem this a very 
probable orientation as the CO2 is optimally positioned for a nucleophilic attack from 
C2 of the octenoyl-CoA.  
 
 
Fig. 51: CO2 docked into the structure of CinF. CO2 is shown as cyan sticks, CinF is shown in 
blue, octenoyl-CoA in pink and NADP in green.  
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4B.2 The thioesterase SpirTE 
4B.2.1 Production and purification of SpirTE 
The purification and initial crystallisation were performed by Christoph Bürth as part 
of his diploma thesis, crystallization of the Se-Met labelled protein was performed by 
Marieke Dieckmann. The plasmid carrying the SpirTE gene was kindly provided by 
Kathrin Buntin in the group of Rolf Müller (Saarland University, Saarbrücken). The 
protein was produced in BL21 cells from 2L LB medium. The cell lysate was applied 
to a Ni-NTA column and SpirTE was eluted by buffer containing 250mM imidazole. 
The elution fractions were tested for purity by SDS PAGE (Fig. 52). 
 
 
Fig. 52: SDS gel of SpirTE Ni-NTA chromatography. M: marker; S: soluble lysate; P: insoluble 
lysate; F: flow through; W1-3: wash; E1-4: elution fractions 
 
The protein was further purified by gel filtration using a 16/60 SD200 column (GE 
healthcare). The protein eluted as a single peak and the corresponding fractions 
were analysed by SDS PAGE (Fig. 53). The protein elutes at about 75ml, which 
corresponds to a molecular mass of about 80kDa. Considering the calculated 
molecular mass of a SpirTE monomer of 33kDa this results in a calculated oligomeric 
state of 2.4, indicating a dimer, similar to other PKS thioesterases (Tsai et al. 2001).  
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Fig. 53: SpirTE gel filtration. A: Chromatogram. B: SDS gel. M: marker; 1-8 elution fractions (elution 
volume 70ml - 82ml). 
 
The total yield of pure SpirTE from 1L culture was 30mg. After gel filtration, the 
protein was concentrated to 7mg/ml for crystallization. 
 
4B.2.2 Crystallization of SpirTE 
Initial crystallization screens resulted in several hits under conditions with pH around 
5 and PEG as precipitant. The crystals occurred either as clusters of needles or as 
separate rod-shaped crystals, often together with precipitate (Fig. 54).  
 
 
Fig. 54: Initial SpirTE crystals. a: 0.1 M MES pH 6.5, 10 5 b: 0.2M NaCl, 0.1 M Na-phosphate pH 
6.2, 10 % (w/v) PEG8000, c: 0.2 M Na-acetate, 0.1 M Na-citrate, pH 5.5, 5 % PEG4000 
 
Optimization of the crystallization conditions (10 % PEG8000, 0.15 M NaCl, 0.2 M 
Na-phosphate pH 6.2) in 24-well hanging drop plates and seeding resulted in large 
rod-shaped crystals which diffracted to about 3 Å (Fig. 55).  
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Fig. 55: Optimized SpirTE crystals. A: rod-shaped crystal; B: rhombohedrical crystal. Both from 
10% PEG8000, 0.15 M NaCl, 0.2 M Na-phosphate pH 6.2 
 
SeMet-labelled protein was used to obtain crystals for anomalous scattering 
experiments to obtain phase information. These, however, sometimes had a different 
morphology than the original crystals. They were of rhombohedrical shape and often 
displayed macroscopic twinning. Seeding experiments resulted in large, single 
crystals, one of which diffracted up to 2.5 Å.  
 
4B.2.3 Data collection 
A native dataset of a rod-shaped SpirTE crystal was collected at the beamline ID29 
at the ESRF (Grenoble), which diffracted up to 2.9 Å. The space group was 
determined to be C222 with the unit cell constants a=121.3 Å, b=168.9 Å, c=170.5 Å. 
Molecular replacement was tried with several homologues such as 1KEZ (DESB TE) 
and 2HFK (PIK TE) as well as with parts of these structures, but no solution could be 
obtained. Thus, a SAD dataset of a SeMet-labelled crystal with a rhombohedrical 
shape was measured at the same beamline. This crystal grew in the space group 
P21212 with the unit cell constants a=99.5 Å, b=167.0 Å, c=41.2 Å. Data processing 
was carried out using XDS (Kabsch 2010) and scaling using XSCALE. The Matthews 
coefficient (Matthews 1968) was calculated to VM = 2.86 Å3 Da-1 indicating two 
monomers per asymmetric unit corresponding to a solvent content of 57%. Heavy 
atom positions and initial phase information were obtained by ShelX (Sheldrick 2008) 
which detected 6 of 10 possible selenium sites. These heavy atom sites were used in 
Phaser (McCoy et al. 2007) for heavy atom site refinement and detecting 3 additional 
sites. The resulting phases were subjected to density modification with Parrot 
(Cowtan 2010) and a model was built into the improved density using Buccaneer 
(Cowtan 2006) which built most of the two protein chains. Manual model building and 
A B 
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refinement were performed with Coot (Emsley et al. 2010) and Refmac5 (Murshudov 
et al. 1997). In the end waters were placed by Coot and a final TLS refinement 
(Painter & Merritt 2006a) step using five TLS groups per monomer as determined by 
the TLS Motion Determination Server (Painter & Merritt 2006b) was carried out with 
REFMAC5. The final R values were 21.2 %/ 27.2%, (Rwork / Rfree), respectively. 
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Table 13: SpirTE data collection and refinement statistics 
 SAD 
X-ray source ESRF ID29 
Space group P21212 
Unit cell dimensions  
a, b, c (Å) 
99.6, 167, 41.3 
Wavelength (Å) 0.9793 
Resolution (Å) 64-2.45 (2.58-2.45) 
Measured reflections 355450 (51838) 
Unique reflections 26249 (3790) 
I/σI 14.8 (3.8) 
Completeness (%) 100 (100) 
Redundancy 13.5 (13.8) 
Rmerge (%) 9.3 (56.5) 
Wilson B factor (Å2) 67.7 
Solvent content (%) 57% 
  
Rwork (%) 21.2 
Rfree (%) 27.2 
Protein atoms 4023 
Solvent atoms 86 
r.m.s.d. from ideal geometry:  
Bond lengths (Å) 0.0216 
Bond angles (°) 1.698 
Average B-factor (Å2):  
Protein (chain A) 22.2 
Protein (chain B) 22.9 
Solvent 23.3 
Ramachandran plot (%):  
Favoured region 93.7 
Allowed region 5.6 
 
4B.2.4 SpirTE structure 
The asymmetric unit of the SpirTE crystals contains two monomers. These 
superimpose very well as shown by an rmsd of 0.53 Å for Cα atoms except for the 
loop connecting β6 and β7. For both chains residues 21 to 283 could be built. The 
protein consists of two domains: a hydrolase core domain and an α-helical lid or 
dimerisation domain (Fig. 56). The hydrolase domain exhibits an α/β-hydrolase fold 
lacking the first β-strand (Ollis et al. 1992). Thus, it consists of a central seven-
stranded β-sheet, which is all parallel except for the first strand, surrounded by four 
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α-helices (α3-5 and α8). The lid domain consists of four helices (α1/2 and α6/7). 
Helices α6 and α7 pack against helices α1 and α2 in a kind of hash key arrangement. 
These latter two helices mediate an extensive interface between the two monomers 
in the asymmetric unit with an interface area of 818 Å2 and a ∆G of -18.5kcal/mol. 
This is the only significant interface as judged by the PISA server (Krissinel & Henrick 
2007) and has been observed in all other PKS TE domain structures so far (Akey et 
al. 2006; Samel et al. 2006; Tsai et al. 2001). Thus, this is probably the dimer which 
has been suggested by gel filtration. 
 
Fig. 56: SpirTE structure. A: Cartoon diagram of a SpirTE monomer colored by secondary structure 
(helix: blue, strands: red and loop: white); B: Topology diagram; the positions of the residues of the 
catalytic triad are marked by black circles. 
 
4B.2.5 Active site 
In a surface representation a tunnel between the two domains of the protein is visible 
(Fig. 58A and B) which spans the entire protein. This tunnel is roughly 25 Å long and 
in the middle about 6 Å in diameter. The active site of the protein is located 
approximately at the centre of this tunnel. SpirTE has the catalytic triad Ser150, 
His261 and Asp177. Ser 150 is positioned on a loop after β4 and Asp177 on a loop 
after β5 while His 261 is found on a loop after β7 (Fig. 56B). The aspartate forms a 
hydrogen bond to the histidine which thereby becomes more eletronegative (Fig. 57). 
The histidine can thus abstract the proton from the serine which enables the serine to 
attack the thioester bond of the substrate. The backbone nitrogen of residue S151 
A B 
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might act as an oxyanion hole, which donates a hydrogen bond to and thereby 
stabilises the negatively charged oxygen at the tetrahedral intermediate.  
 
 
Fig. 57: Putative reaction mechanism of SpirTE. The catalytic triade S150, H261, D177 catalyses 
the claevage of the thioester bond of the spirangien precursor, while the backbone amide of S151 acts 
as an oxyanion hole to stabilise the tetrahedral intermediate state. 
 
The tunnel opens at one end in spatial proximity (about 16 Å) to the N-terminus of the 
protein (Fig. 58A). In the full-length protein (SpiJ) the ACP domain would be located 
here. Thus, the ACP domain can bind to the entrance of the tunnel and insert the 
PPant-bound spirangien-precursor into the tunnel. The thioester is then cleaved in 
the active site and the free spirangien-precursor can leave the protein via the exit 
tunnel, whereas the empty PPant-arm retracts from the entrance and is ready to take 
up a new substrate. 
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Fig. 58: SpirTE substrate tunnel and active site. A: SpirTE dimer as cartoon and surface showing 
the tunnel between the lid and the hydrolase domain (black arrows). B: Surface view of the substrate 
tunnel with the catalytic triade shown as sticks. C: The substrate tunnel is lined with hydrophobic 
residues (shown as sticks).  
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The substrate tunnel is lined with mostly hydrophobic residues such as I201, W202, 
W205, F208, V102, V210, V189 and V276 and only few hydrophilic patches such as 
those created by Y97 and W202 (Fig. 58C). The first half of the PPant-arm which will 
be inserted into the tunnel is highly hydrophobic. The same is true for the spirangien-
precursor which is the substrate for SpirTE, especially the region that would be 
bound to the protein. Thus, once the first part of the long and flexible molecule has 
entered the tunnel, the rest will be pulled into the protein by the force of the 
hydrophobic interactions.  
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5 Discussion 
5A Virulence regulation in pathogenic Yersiniae 
 
5A.1 The transcription factor RovA 
5A.1.1 RovA is a key player in virulence regulation  
The transcription factor RovA plays a major role in the pathogenesis of all pathogenic 
Yersinia species (Heroven & Dersch 2010). In enteropathogenic Yersinia it is the 
main regulator in a complex regulatory network controlling the expression of the 
adhesin invasin which is required for rapid uptake of the bacteria through the host 
epithelium. RovA has been shown to act as a protein thermometer (Herbst et al. 
2009). Thus, it exhibits strongly reduced DNA binding affinity at 37°C compared to 
25°C and is degraded proteolytically in vivo. To gain additional insight into the 
complex regulation of RovA in this work it was further characterised using biophysical 
methods and the structure was solved in complex with DNA and in complex with the 
potential inducer molecule salicylate. 
 
5A.1.2 Small aromatic compounds act as inducers for RovA 
For several MarR-type transcription factors small inducer molecules have been 
described that bind to the proteins and thereby influence their DNA binding capability 
(Wilkinson & Grove 2006). These include small aromatic compounds such as 
salicylate (Alekshun & Levy 1999), uric acid (Wilkinson & Grove 2004) and even 
chlorinated compounds (Providenti & Wyndham 2001). For RovA no inducer 
molecule has been described so far. Therefore, several small compounds were 
tested for their affinity to RovA by Thermofluor assay. These assays showed that 
RovA binds to small aromatic acids such as salicylate and benzoate with millimolar 
affinity. Additional hydroxyl groups as in 2,3-dihydroxybenzoate or 4-
hydroxybenzoate bind with similar affinity, whereas amino groups as in anthranilate 
or 4-aminobenzoate resulted in a reduced affinity and phenylalanine did not bind at 
all. Additionally, uric acid was tested and also found not to bind to RovA. Surprisingly, 
cinnamate and 3-chlorocinnamate were found to bind to RovA with higher affinity 
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than the other compounds. Often, the compounds that bind to MarR-type proteins are 
related to the genes they regulate such as chlorobenzoate, which is an inducer of 
CbaR which regulates genes involved in the degradation of chlorobenzoate 
(Providenti & Wyndham 2001). Unfortunately, for RovA no such relationship is 
evident. Therefore, it is still unclear which compounds act as inducers for RovA in 
vivo. To understand the effect of inducer binding to the function of RovA, gel shift 
assays in the presence of salicylate were performed. These showed that addition of 
salicylate to RovA reduces its DNA binding affinity and thereby acts as an inhibitor of 
RovA. Similar results have been obtained for other MarR-type proteins such as MarR 
from E. coli (Martin & Rosner 1995), ST1710 from Sulfolobus tokodaii (Kumarevel et 
al. 2009) and MTH313 from Methanobacterium thermoautotrophicum (Saridakis et al. 
2008). CD spectroscopy was used to analyse the impact of salicylate binding on the 
conformational flexibility of RovA. RovA shows a slow, reversible decrease of α-helix 
content during an increase in temperature from 20°C  to 37°C. Upon addition of 
salicylate, however, this change is strongly reduced. This is probably because RovA 
is stabilised and locked in a certain conformation when bound to salicylate and thus 
less prone to conformational flexibility. A stabilisation RovA was also observed in vivo 
by the addition of salicylate to Y. pseudotuberculosis cells. This indicates that a small 
aromatic compound, similar to salicylate, might play a role in the regulation of RovA 
production. 
In vivo, a stabilisation of RovA has been observed in bacteria cultures that have 
reached the stationary phase (Herbst et al. 2009). Here, even at 37°C RovA is 
degraded only very slowly. Experiments have been conducted to show that this 
stabilisation is conferred by the medium in which the cells were grown (Herbst, 
unpublished results). To this end, Y. pseudotuberculosis cells were grown to 
stationary phase and the removed from the medium by centrifugation. The cleared 
medium was then used to grow bacteria in the exponential phase. These bacteria 
now also showed a stabilised RovA as if they had been grown in stationary phase. 
These results suggest that there might be a small molecule that is secreted into the 
medium by bacteria growing in stationary phase that stabilises RovA. Whether this 
molecule directly binds to RovA and the chemical nature of this molecule are so far 
unknown and will be subject of further research. It is also possible that this or a 
similar molecule is also produced by E. coli and was visible as the undescribed 
density in the RovA/DNA structures.  
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5A.1.3 The RovA mutant P98S is proteolytically stable  
While the sequence of RovA is identical in Y. pestis and Y. pseudotuberculosis, the 
Y. enterocolitica RovA is slightly different. One of the mutations (P98S) has been 
shown to lead to a stabilisation in vivo and it was proposed that this mutation might 
influence the thermosensing ability of RovA. Thus, the DNA binding, salicylate 
binding and thermal stability have been tested in vitro. Together, these tests showed 
that RovA P98S behaves exactly like the wild type in vitro. Therefore, it seems 
probable that the difference in stability observed in vivo is due to a reduced 
proteolytic degradation. Possibly, this mutation hampers the recognition of RovA by 
the protease. 
 
5A.1.4 RovA A10F, a stable mutant in vitro 
As the binding of small molecules such as salicylate to RovA has been shown to 
have a strong impact on the behavior of RovA in vitro and in vivo, mutants of RovA 
were generated in order to block the ligand binding cavity in RovA. Towards this end, 
two small amino acids (G6 and A10), which line the cavity, were selected because 
their in silico mutagenesis to phenylalanine promised to block ligand binding in the 
cavity (Fig. 59A and B). Both mutants were produced and tested for their stability and 
salicylate binding capability by ThermoFluor and CD measurements. While the G6F 
mutant behaved like the wild type, the A10F mutant showed a significantly higher 
melting temperature than the wildtype. The melting temperature of RovA A10F in the 
absence of salicylate is comparable to the melting temperature of the wild type in the 
presence of 20mM salicylate. RovA A10F still bound salicylate although with a much 
lower affinity than the wild type. Additionally, the CD spectra of RovA A10F at 20°C 
and 37°C indicate a strongly deccreased conformatio nal flexibility of this mutant. 
Therefore, it seems that the phenylalanine sidechain occupies the binding pocket 
where salicylate can bind. This would stabilise the protein and prevent salicylate 
binding. The residual salicylate binding might be explained by incomplete blockage of 
the ligand binding pocket or the presence of another weaker binding site such as 
visible in the structure of RovA with salicylate. To examine the impact of the blockage 
of the ligand pocket on the DNA binding capability, further experiments have to be 
carried out such as gel shift assays and in vivo stability assays. The latter might give 
important insights into the potential role of small molecules in the regulation of RovA. 
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Fig. 59: In silico model of mutagenesis of RovA (A: A10F, B: G6F). RovA is shown in blue, 
salicylate inorange, the mutated residue in white. Steric clashes with neighboring residues are marked 
by disks.  
 
5A.1.4 RovA recognizes DNA in a similar fashion as OhrR 
In this work the first structure of the global virulence regulator RovA from Y. 
pseudotuberculosis has been solved in complex with DNA fragments from the rovA 
and inv promoter region. Two structures of MarR-type proteins in complex with DNA 
have been published so far, OhrR from B. subtilis (Hong et al. 2005) and ST1710 
from Sulfolobus tokodaii (Kumarevel et al. 2009). While the overall DNA binding 
mechanism is similar between RovA and OhrR, with the recognition helix of the HTH 
motif inserted into the major groove of the DNA and the wing contacting the minor 
grove (Fig. 60A), the DNA binding observed for ST1710 seems to be quite different 
(Fig. 60B). In the structure of ST1710, the recognition helix is not inserted into the 
major groove and thus makes only few base-specific contacts with the DNA, whereas 
most contacts are mediated by the wing. Yet, even though the structures of RovA 
and OhrR in complex with DNA are similar, the rmsd of 3.8 Å for common Cα atoms 
is relatively high, mostly due to differences in the long helices of the dimerisation 
interface (Fig. 60A).  
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Fig. 60: Structural alignment of RovA (blue) and OhrR (green) or ST1710 (brown) in complex 
with DNA. A: Comparison of one monomer of RovA and OhrR aligned by their DBDs showing 
differences in the long helices of the dimerisation domain (indicated by a black arrow). B: Comparison 
of one monomer of RovA and ST1710 showing the superficial DNA binding of ST1710 compared to 
RovA. C: A similar DNA binding motif is employed by RovA and OhrR involving an arginine and an 
aspartate residue. D: Different amino acids are used to establish contacts to the DNA at the same 
positions. 
 
While the overall DNA binding by RovA and OhrR is similar, the amino acids that are 
involved in base recognition are different, reflecting their individual DNA specificity 
(Fig. 61). OhrR interacts with the bases of its DNA specifically with six amino acids, 
namely D67, S68, G69 and T70 from helix 4 and R88 and R94 from the wing. Only 
R94, which contacts the DNA in the minor groove, is also present in RovA (R86) (Fig. 
60C). It is also conserved in many other MarR-type proteins and may therefore not 
necessarily be used to gain specificity but rather increase the general DNA binding 
affinity (Hong et al. 2005). Interestingly, even though the other amino acids that make 
specific contact to the DNA are different, the same positions are used to establish 
C D 
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DNA contacts. For example S68 in OhrR recognizes an adenine residue by a 
hydrogen bond while RovA also recognizes an adenine residue at the same position, 
but with a different amino acid (Q60) which is located at the same position in 
therecognition helix (Fig. 60D). Therefore, it seems that the shared fold of the DBD 
allows certain positions to establish contact to the DNA. These positions probably 
mainly define the DNA binding specificity of the protein. 
 
 
Fig. 61: Structure based sequence alignment of RovA with OhrR from Bacillus subtilis. The 
sequences of RovA from Y. pseudotuberculosis and OhR were aligned with ClustalW (Larkin et al. 
2007) and displayed with ESPript2.2 (Gouet et al. 1999). The dimerisation domain is shown by a black 
line, the DNA binding domain by a green line. Residues found to recognize DNA bases specifically are 
denoted by asterisks. 
 
5A.1.5 RovA is a global transcription regulator 
Overall, RovA does have less amino acids that specifically interact with the DNA than 
OhrR. This reflects the role of RovA as a general transcription factor, responsible for 
the regulation of several genes in the genome (Ellison et al. 2004). This is in contrast 
to many other MarR-type regulators such as OhrR which only binds to one defined 
binding site, which is nearly perfectly palindromic (Fuangthong et al. 2001) and MarR 
which binds to two nearly palindromic sequences (Martin & Rosner 1995). For RovA, 
however, no defined palindromic sequence could be found. Instead, RovA was found 
to prefer AT-rich sequences (Heroven et al. 2004). Furthermore, in this work the 
structure of RovA was solved in complex with two different DNA fragments which 
have only 11 out of 21 identical bases. This further underlines the variable nature of 
the DNA recognition of RovA. Additionally, it was found that OhrR and MarR bind to 
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their target DNA with high affinity (KD=5nM and 1nM, for OhrR and MarR, 
respectively) (Fuangthong & Helmann 2002; Martin & Rosner 1995) whilst , for 
example, the affinity of RovA with the inv promoter region is much lower (Kd=32nM 
and 45nM for binding site I and II, respectively) (Herbst et al. 2009). Therefore, it can 
be concluded that RovA interacts with the DNA specifically only at few positions. This 
explains the promiscuity of the DNA binding which is required for its role as a global 
transcription factor.  
 
5A.1.6 RovA relieves silencing by H-NS 
In contrast to OhrR which acts as a repressor by binding in the promoter region of its 
target gene, RovA acts as an activator of inv as well as its own gene. This activation 
is achieved by displacement of the repressing nucleoid-associated protein H-NS 
(Ellison & Miller 2006; Heroven et al. 2004; Tran et al. 2005). RovA and H-NS 
compete for binding to overlapping sequences in the promoter regions of rovA and 
inv. H-NS binding to DNA has been shown to lead to bending, compaction and also 
to bridging between distant DNA strands leading to repression of transcription of 
adjacent genes (Dame et al. 2005; Noom et al. 2007). An additional factor that is 
needed for repression of rovA transcription is the LysR-type transcription regulator 
RovM  which is also suspected to induce bending of the rovA promoter region 
(Heroven & Dersch 2006). It has been suggested that the binding of H-NS and RovM 
to DNA might lead to the formation of a stable inhibitory complex which loops the 
DNA and thereby prevents binding of the RNA polymerase (Heroven & Dersch 
2006). On the other hand, the RovA DNA complex shows the DNA in a linear 
conformation. This suggests that the inhibitory H-NS/RovM complex can be 
displaced by elevated concentrations of RovA. This would alleviate the bending of 
the DNA by the enforced linear conformation, where RovA has bound and thereby 
allows RNA polymerase binding and gene transcription. 
 
5A.1.7 Comparison of RovA and SlyA DNA binding sequences 
The structure of RovA in complex with DNA is overall similar to the yet unpublished 
structure of the close homologue SlyA from Salmonella typhimurium (pdb code: 
3DEU, 75% sequence identity) in complex with salicylate with an rmsd of 1.65 Å for 
common Cα atoms. Similar to RovA, SlyA has been shown to be a global 
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transcription factor regulating the expression of a large number of genes involved in 
virulence and resistance to oxidative stress (Buchmeier et al. 1997). Nearly all amino 
acids which are different between these two proteins are on the surface, mainly on 
the two C-terminal helices (Fig. 63). None of them is directly involved in DNA binding. 
We thus propose that SlyA and RovA should exhibit the same DNA binding 
specificity. However, the DNA consensus binding sequence of SlyA that has been 
published is quite different from the sequences in the RovA structures (Stapleton et 
al. 2002). Most notably, at positions 1 and 12, in which an adenine residue is 
contacted by Q60, the SlyA consensus sequence has a thymidine (Fig. 62), which 
would not be recognized by the protein as in one monomer of the RovA/rovA1A 
structure. At positions 4, 5, 8 and 9 a strong preference for G or C has been 
determined for SlyA, whereas these bases occur only rarely in RovA binding 
sequences. These differences are surprising as the DBDs of RovA and SlyA are 
nearly identical. Therefore, additional experiments have to be carried out to 
investigate these observed discrepancies.  
 
 
Fig. 62: Comparison of the DNA sequences from the RovA/DNA structures compared with the 
consensus sequence for SlyA (Stapleton et al. 2002). The positions that are specifically 
recognized by amino acids in the RovA structures are marked by boxes. Deviations at these positions 
are marked by red circles.  
 
5A.1.8 Mutations in RovA and SlyA defective in DNA binding 
Several mutants of RovA and SlyA defective in DNA binding have been described, 
which can now be explained by the presented structure. For RovA single mutations in 
residues 44, 51, 60, 61 and 71 (Tran et al. 2005) and in SlyA mutations of amino 
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acids 52, 53 60, 63, 64, 65, 67, 70, 71, 74, 75, 77, 78, 79, 80, 85, 86, 88 and 90 were 
found to strongly reduce DNA binding affinity (Haider et al. 2008). All of these SlyA 
residues are conserved in RovA, except S77 which is a threonine in RovA and Q79 
which is a histidine in RovA (Fig. 63). 
P44 is located in a loop between helices α2 and α3 and is probably required for 
proper positioning of these helices. The mutation Q51R shows only a mild effect on 
DNA binding. It is not clear why it would impact DNA binding, as the residue is 
disordered in the DNA complex structure. P61 is positioned at the end of helix α4 and 
recognizes the DNA via hydrophobic interactions. A mutation of this residue to leucin 
would lead to strong steric interactions with the DNA and was thus shown to 
completely abolish DNA binding.  
 
Amino acids A53, L52, L63, L67, L70 and I90 form the hydrophobic core of the wHTH 
domain and are thus probably indispensable for its stability. G74 and L75 are located 
on the loop between α4 and the first β-sheet of the wing (β1) and are responsible for 
correct positioning of the wHTH domain by hydrophobic interactions as well as 
hydrogen bonds with helix α6 from the dimerization domain. V64 could be seen to be 
responsible for hydrophobic interactions with a thymidine residue at position 5 from 
the centre of pseudosymmetry. The mutation V64I probably leads to a steric 
hindrance with the DNA und thus to reduced affinity. The important role of Q60 and 
R86 in recognizing bases has been described above and is reflected by a complete 
loss of binding affinity for the respective alanine mutants in gel shift experiments. 
R65, on the other hand, which also seems to be crucial for DNA binding in vitro, is 
not visible in our structures in complex with DNA due to flexibility. It is well positioned 
to allow binding to bases in the major groove of the DNA and it may be necessary for 
binding to a base which is not present in this position in our structure. R78 and K88 
are directly involved in hydrogen bonds with the phosphate backbone, while E71 
interacts with to R78 and thus keeps it in place. Q79 (H79 in RovA) might be 
important for keeping the wing in place as it forms a hydrogen bond with R89 from 
the other β-strand of the wing. The role of S77 (T77 in RovA) and T80, on the other 
hand, is not visible from the structure.  
 
In conclusion, the role of most of the mutations that have been identified to hamper 
RovA or SlyA DNA binding can be explained by the structure presented in this work.  
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Fig. 63: Structure based sequence alignment of RovA with SlyA from S. typhimurium. The 
sequences of RovA from Y. pseudotuberculosis and SlyA were aligned with ClustalW (Larkin et al. 
2007) and displayed with ESPript2.2 (Gouet et al. 1999). The dimerisation domain is shown with a 
black line, the DNA binding domain by a green line. Residues found to recognize DNA bases 
specifically are denoted by asterisks and residues which were mutated in this work are marked by 
arrows. 
 
5A.1.9 The RovA-apo structure shows conformational flexibility 
The structure of RovA-apo could only be solved by molecular replacement using the 
structure of RovA in complex with DNA. The molecular replacement found five 
monomers in the asymmetric unit and another monomer was detected and placed 
manually during refinement. However, this monomer showed only weak or no 
electron density in those parts of the protein which are not directly involved in dimer 
formation, namely the DBD. Comparison of the RovA monomers showed that the 
conformation of RovA is probably quite flexible without stabilising binding partners 
such as salicylate or DNA. Interesting is also the superposition of the structure of 
RovA-apo and the DNA bound form (Fig. 64A). The rmsd for all common Cα atoms 
between the RovA in complex with the inv1 DNA and RovA apo is 1.1 Å / 2.4 Å / 2.3Å 
for RovA-apo dimer AB/CD and EF, respectively. This demonstrates that the dimer 
AB has a conformation which is most similar to the DNA bound form, while dimers 
CD and EF are more different. The superposition of one chain of each dimer shows 
that the DBD of the other chain has moved in the apo structure relative to the DNA-
bound form. This conformational change places the DBD closer towards the DNA 
and reduces the gap between the two DBDs in the dimer. The movement is more 
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pronounced for RovA-apo dimers CD and EF with a distance of 6.4 Å and 6.8 Å, 
respectively, between the Cα atoms of Q60, an important residue in the recognition 
helix, compared to DNA-bound RovA. This distance is only 4.3 Å for RovA-apo dimer 
AB. Similar conformational flexibility has been observed also for other MarR-type 
transcription factors such as MexR (Lim et al. 2002). As the conformation of all RovA-
apo dimers would lead to a steric clash with the DNA, it can be concluded that RovA 
without ligands can probably perform a twisting motion (similar to the vibrational 
mode in a water molecule) and only the open form is able to bind to DNA (Fig. 64A). 
Interestingly, a different, scissoring conformational change between the apo form and 
the DNA bound form has been described for OhrR (Fig. 64B) (Hong et al. 2005). 
Here, the apo form assumes a more open conformation, moving the DBD away from 
the DNA, rather than closer to the DNA. Therefore it seems that different 
conformations are used by proteins from the same family. 
 
 
Fig. 64: Conformatonal movements upon DNA binding of MarR-type proteins (indicated by 
black arrows). A: Superposition of one chain of RovA/DNA (blue) and RovA apo dimers AB (red) and 
CD (green). B: Superposition of one chain of OhrR/DNA (blue) and OhrR-apo (red).  
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5A.1.10 Structure of RovA in complex with salicylate 
The structure of RovA in complex with salicylate was solved by using the 
unpublished structure of SlyA from Salmonella typhimurium as a model for molecular 
replacement. Comparison of the structures of RovA/sal with RovA/DNA shows that 
both adopt a similar fold. However, a conformational change can be observed which 
results in as rmsd for all common Cα atoms of 2.3 Å (Fig. 65A). RovA/sal exhibits a 
closed conformation where the DBDs are closer together than in the DNA bound 
structure. In order to bind DNA the protein would have to open up in a scissoring 
motion. A similar motion was detected for OhrR between apo and DNA bound form 
(Fig. 64B), only that the apo form was in a more open conformation than the DNA 
bound form.  
 
 
 
Fig. 65: Conformational differences between RovA bound to DNA (blue) and salicylate (green). 
A:.Side- and frontview of overall structures aligned by one monomer showing the scissoring motion 
that has to occur for RovA/sal to allow DNA binding (indicated by black arrow). B: Detailed view of the 
ligand binding pocket. The FO-FC map of RovA/DNA is shown as blue mesh at 4 sigma. 
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Two salicylate molecules are bound to every RovA monomer. One salicylate 
molecule was found at the surface of the DBD, the other in a mostly hydrophobic 
pocket at the dimerisation interface. It is interesting to note that the undescribed 
density which was detected in the structures of RovA in complex with DNA was found 
in the same pocket (Fig. 65B). However, it was not possible to explain the density 
with any of the substances used in the crystallization condition. RovA has been 
shown in this study to bind to a variety of small hydrophobic molecules and it is 
therefore possible that such a molecule from the expression host has been carried 
into the crystallisation. The superposition of the hydrophobic pocket of RovA/sal and 
RovA/DNA also reveals that R14 which is oriented directly towards the carboxy-
group of the salicylate molecule in the RovA/sal structure points into a different 
direction in the RovA/DNA structure (Fig. 65B). Obviously, the sidechain of R14 
rotates towards the pocket to compensate the negative charge of the carboxy-group 
of the salicylate. 
 
The hydrophobic pocket seems to be involved in ligand binding in many MarR-type 
proteins. Several proteins from this class such as ST1710, MTH313 or SlyA 
(Kumarevel et al. 2009; Saridakis et al. 2008) have been crystallized with salicylate 
and salicylate molecules were bound in this pocket in most of them (Fig. 66). 
Additionally, superposition of RovA with OhrR, which is regulated by the oxidation of 
the reactive cysteine 15, shows that this cysteine is located in direct vicinity to the 
salicylate molecule of RovA. It is therefore probable that conformational changes at 
this position either by binding of a ligand such as salicylate (as in RovA) or amino 
acid modification (as in OhrR) represent a conserved mechanism to influence the 
DNA binding affinity of MarR-type proteins.  
 
The second salicylate binding site, however, might be an artefact of the unnaturally 
high salicylate conditions. The salicylate is held in place by only weak undirected 
hydrophobic interactions and this binding site is also visible in the structure of SlyA 
(Fig. 66). The structure of SlyA, which shares a high sequence identity with RovA, is 
very similar to the RovA structure with an rmsd for common Cα atoms of 1.3 Å. It has 
salicylate molecules bound in the same positions as RovA, however it also has 
another molecule bound to the surface of the dimer interface. Interestingly, so far, 
only for MarR have salicylate molecules bound to the DBD been described. Yet, 
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these are bound in positions distinct from the binding site in RovA. It is therefore 
questionable whether the observed salicylate binding to the surface of the DBD is 
physiologically relevant.  
 
 
Fig. 66: Comparison of RovA in complex with salicylate with other related proteins. Stereo 
representation of superposition of one monomer of RovA/sal (blue, Y. pseudotuberculosis) with SlyA 
(yellow, 3DEU, S. typhimurium), MarR (orange, 1JGS, E. coli), ST1710 (purple, 3GF2, Sulfulobus 
tokodaii), MTH313 (rose, 3BPX, Methanobacterium thermoautotrophicum) and OhrR (green, 1Z91, B. 
subtilis). The protein is shown as ribbon, salicylate molcules and C15 of OhrR are shown as sticks. 
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5A.2 The transcription regulator RovM 
5A.2.1 RovM is a repressor of RovA 
In addition to the main regulator RovA, there are several other proteins and also 
RNAs involved in the complex regulatory network regulating inv expression. One of 
these is the LTTR RovM that acts together with H-NS to repress rovA expression 
(Heroven & Dersch 2006). It links the carbon storage regulator system (CSR), which 
is thought to be involved in sensing the availability of nutrients, to the RovA system 
and also influences flagellar motility (Heroven et al. 2008). To gain deeper insights 
into how this protein functions we investigated the structural details of RovM. We 
were able to produce full-length RovM as well as the effector binding domain of 
RovM (RovM-EBD), determine their oligomeric state and solve the structure of RovM-
EBD. 
 
5A.2.2 Comparison with other LTTR structures 
The structure of RovM-EBD (Quade et al. 2011) was superimposed with the structure 
of the EBD of CynR from E. coli (Knapp & Hu 2009), with which it shares the highest 
sequence identity (21%) of all known LTTR EBD structures (Fig. 67A), with an 
r.m.s.d. of 2.15 Å for all common Cα atoms. Minor structural deviations are only found 
for exposed loop regions. CynR has been shown to exist as a dimer in solution. 
Thus, the structure of the CynR dimer was aligned with the BB`- dimer of RovM, 
which indicates that the BB`-interface is indeed the physiological interface, which is 
conserved among all LTTR EBDs crystallized to date (Fig. 67B). 
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Fig. 67: Superposition of RovM-EBD with CynR. RovM-EBD is shown in blue, CynR in gold. A: 
monomers; B dimers. 
 
An alignment of the sequences of RovM and its homologues CynR (E. coli) (Knapp & 
Hu 2009), CbnR (Ralstonia eutropha) (Muraoka et al. 2003) and BenM 
(Acinetobacter baylyi) (Ezezika et al. 2007) shows a high degree of conservation 
within the DBDs, indicating a conserved DNA binding mechanism (Fig. 68). In 
contrast, the EBD has only few conserved residues, mostly hydrophobic residues in 
the core of the protein. In particular, the C-terminal region is very dissimilar between 
the homologues. This distribution of conserved residues has also been observed for 
other classes of transcription factors such as the MarR family, which have a mostly 
conserved DBD with only few mutations to adapt to new promoter sequences and a 
weakly conserved ligand binding domain that allows binding of very different inducer 
molecules (Wu et al. 2003). 
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Fig. 68: Structure based sequence alignment of RovM with other LTTR proteins. The 
sequences of RovM (Y. pseudotuberculosis), BenM (Acinetobacter baylyi, pdb code 2f7a), CbnR 
(Ralstonia eutropha, pdb code 1ixc) and CynR (E. coli, pdb code 3hfu) were aligned with ClustalW 
(Larkin et al. 2007) and displayed with ESPript2.2 (Gouet et al. 1999). 
 
Of the known LTTR structures, full length RovM has the highest sequence identity to 
CbnR (20.4%; Fig. 68). A superposition of RovM with the structure of a monomer of 
the full-length CbnR shows that the EBD-Is align quite well, whereas the EBD-IIs 
seem to be tilted with respect to the EBD-I (Fig. 69A) (Muraoka et al. 2003). In the 
full-length RovM the DBD would be at the N-terminus of the protein, connected to the 
EBD via a long linker helix. The DBD and the linker helix could easily adopt a 
conformation very similar to that of CbnR as there are no clashes in this alignment.  
Full length CbnR is a tetramer, which was also shown in this study to be true for full 
length RovM. The RovM-EBD on the other hand is a dimer in solution. Superposition 
of the RovM-EBD BB´-dimer with the CbnR tetramer shows that the RovM-EBD 
dimer is arranged in the same way as the dimers of the EBDs of CbnR (Fig. 69B). 
The linker helices and DBDs could be oriented in the same fashion as in CbnR 
124  DISCUSSION 
allowing DNA binding at two distant sites and DNA bending, which has been shown 
for RovM (Heroven & Dersch 2006).  
 
 
 
 
 
Fig. 69: Superposition of the structures of RovM-EBD and CbnR and BenM. RovM-EBD is shown 
in blue, CbnR in red. A: monomers; B: Stereo image of RovM-EBD dimer and CbnR tetramer; C: 
Superposition of two RovM and CbnR EBDs connected via the tetramer interface showing the 
resultant angle between the subunits. D: Superposition of RovM and BenM (cyan) connected via the 
tetramer interface showing a shift of the subunits between RovM and BenM. 
 
In CbnR the interaction between the two dimers is mainly mediated by helix V of one 
subunit with the same helix of another subunit, related by a two-fold axis (Muraoka et 
al. 2003). This kind of interaction, called tetramer interface, has also been detected in 
other full-length LTTR structures, namely BenM (Ruangprasert et al. 2010) and DntR 
(Smirnova et al. 2004). A similar interaction is also present in the RovM-EBD 
structure called AA`` interface. Here the interactions are mostly mediated by helix 3 
(which corresponds to helix V in CbnR) and helix 2. Yet, this interface varies 
considerably between the different structures. This is easily visualized by the angle 
between the two symmetry related helices 3 and 3`. In the CbnR structure the two 
helices are approximately orthogonal to each other (86°), whereas the angle is 129° 
for DntR and 152° for BenM (Ruangprasert  et al. 2010). In contrast, in the RovM-
B A 
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EBD structure these two helices are nearly parallel with an angle of 172°. Thus, the 
two EBDs related by the tetramer interface are roughly parallel to each other in 
CbnR, whereas they are nearly orthogonal in RovM-EBD (Fig. 69C). The structure in 
which the angle is closest to RovM-EBD is BenM, where the EBDs are also nearly 
parallel. But, in comparison with RovM-EBD, in BenM the EBDs are also shifted 
relative to each other (Fig. 69D). This shows that even though several LTTRs use the 
same interface, the resulting oligomeric structures are quite different.   
To determine whether it would be possible for RovM-EBD to form a tetramer similar 
to that of CbnR (two pairs of EBDs connected via the tetramer interface between one 
EBD from each pair), four B subunits were picked accordingly (Fig. 70). Yet, in such 
an orientation the N-termini of two subunits were positioned very close to each other 
so that the linker helices in a full-length protein would probably clash. It thus seems 
unlikely that the full-length RovM tetramer would form in this manner. In the full-
length RovM the strong interaction between the linker helices would probably 
dominate over the weak tetramer interaction and there might be no interaction 
between the EBD pairs as seen in 2ESN. On the other hand, the strong EBD 
interface in the asymmetric unit of RovM-EBD might also play a role in forming the 
tetramer or in cooperative binding of several RovM tetramers. 
 
 
Fig. 70: Tetrameric assembly of RovM in the crystal packing similar to the tetramer of CbnR. 
The black arrow indicates a potential clash of the full-length RovM if oriented in this fashion. 
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5A.2.3 Analysis of inducer binding sites in RovM 
For several LTTR proteins inducers have been described that influence the gene 
regulation of these proteins. For some of these proteins such as BenM it was 
possible to solve the structure in complex with its inducer (Ezezika et al. 2007). The 
inducer molecule (in this case cis, cis-muconate) was shown to bind in the cleft 
between EBD-I and EBD-II and binding resulted in a tilting of the two domains 
towards each other. This movement is thought to be relayed to the DBDs via the long 
linker helices and thus influence DNA binding. BenM was also shown to contain a 
secondary ligand binding site in EBD-I between helix 1 and sheet 4, where a 
benzoate molecule was bound (Ezezika et al. 2007). Fig. 71A shows the positions of 
both ligands after alignment with the RovM structure. The inspection of the primary 
binding site shows that there is a cavity in RovM, which is lined with few hydrophobic 
and several hydrophilic residues, some of which are similar in BenM (Fig. 71B). Yet, 
the cavity is much shallower than in BenM indicating that RovM would bind a smaller 
ligand than BenM.  
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Fig. 71: Comparing BenM (green) ligand binding sites with the structure of RovM-EBD (blue). 
BenM ligands cis, cis-muconate and benzoate, are both shown as yellow sticks A: Cartoon and surface 
display of RovM-EBD. B: Stereo view: comparison of primary binding site residues between RovM-EBD 
and BenM. C: Stereo view: comparison of secondary binding site residues between RovM-EBD and 
BenM. 
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A cavity for the secondary binding site on the other hand is not visible for RovM. The 
ligand clashes with some side chains such as L113 and L166 and even the backbone 
of helix 1 (Fig. 71). Yet, the residues that form the secondary binding site in BenM 
are very similar to those in RovM. Thus, only after conformational changes in RovM 
might a secondary binding site similar to that observed in BenM become accessible. 
Future work will concentrate on finding inducer molecules for RovM and analysing 
their role in the regulation of invasin and other Yersinia virulence factors. 
 
5A.2.4 Comparison between RovM from pathogenic Yersinia species  
Y. pseudotuberculosis and Y. enterocolitica are related pathogens, which are both 
taken up via the faecal-oral route and cause similar diseases. Both use the same 
regulatory system including RovA and RovM to regulate the expression of virulence 
factors such as invasin. Even Y. pestis, a vector-borne pathogen which enters its 
host via a completely different route and causes different diseases, relies on this 
system for virulence factor regulation. The sequence of RovM is fully conserved 
between Y. pseudotuberculosis and Y. pestis, whereas there are some differences 
between Y. pseudotuberculosis and Y. enterocolitica (Fig. 72).  
 
 
Fig. 72: Structure based sequence alignment of RovM from Y. pseudotuberculosis and Y. 
enterocolitica. The sequences were aligned with ClustalW (Larkin et al. 2007) and displayed with 
ESPript2.2 (Gouet et al. 1999). 
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Few mutations are found in the DBD, which shows a conserved DNA binding 
mechanism, and the first 45 amino acids of the EBD. Most of the mutations can be 
found at the end of helix 7 and the following region, which is probably unstructured 
and was not detectable in the electron density due to its flexibility. Mapping the 
changed residues onto the structure of RovM demonstrates that most of the 
mutations can be found on the surface of the protein (Fig. 73). Yet, two mutations 
(L197P and Y198F) are located within the potential inducer binding site between 
EBD-I and EBD-II. So far, it is unclear what the inducer of RovM is or whether there 
is one at all. But since RovM has been shown to mediate invasin expression in 
response to nutrient availability, it is conceivable that some small molecule 
connected to metabolism may act as an inducer for RovM. Whether the mentioned 
mutations in the ligand binding pocket affect the binding selectivity or affinity of the 
putative ligand will be subject of further investigation. RovA and RovM genes have 
also been found in virtually all other Yersinia species with the most distant RovM 
from Y. intermedia sharing 88% sequence identity. Yet, these other species are non-
pathogenic in humans and have no invasin gene. Probably, the whole RovA/RovM 
regulatory system originally performed other functions and has evolved in pathogenic 
species to regulate virulence genes as well.  
 
 
Fig. 73: Differences in RovM between Y. pseudotuberculosis and Y. enterocolitica, shown as 
orange sticks.  
 
In conclusion we have presented the structure of RovM-EBD from Y. 
pseudotuberculosis as well as analysis of the oligomeric state of RovM-EBD and full 
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length RovM. RovM-EBD exists as a dimer, while full length RovM probably 
assembles into a tetrameric dimer of dimers like the homologue CbnR. Additionally, a 
cavity was detected in RovM-EBD which could serve as a binding site for a small 
inducer molecule. 
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5B Polyketide synthases 
 
5B.1 The octenoyl-CoA carboxylase/reductase CinF 
5B.1.1 CinF generates an unusual building block for polyketide synthesis 
Many drugs that are in use today, for example as antibiotics or anti-cancer drugs, are 
derived from natural products that are produced by polyketide synthases (PKS). 
These huge multi-enzyme biosynthesis clusters use small building blocks, called 
extender units, to build large, complex molecules with biological activity. A typical 
extender unit is methylmalonyl-CoA that is produced from crotonyl-CoA by so called 
crotonyl-CoA carboxylase/reductases (CCR) via reductive carboxylation. However, 
other extender units have been described such as hexylmalonyl-CoA and 
chloromethylmalonyl-CoA. In order to understand the molecular basis of the reaction 
mechanism as well as the substrate specificity, in this work we have characterised 
biochemically as well as structurally CinF that generates the unusual extender unit 
octenoyl-CoA. 
 
5B.1.2 CinF is a tetramer 
Here we describe the first structure of a carboxylase/reductase. Size exclusion and 
PISA analysis suggest that CinF forms a tetramer. The closest homologous 
structures of CinF, two putative crotonyl-carboxylases/reductases (CCR, pdb codes: 
3HZZ and 3KRT, both with 51% sequence identity) which are both yet unpublished, 
also appear to form a similar tetramer. Tetrameric assemblies have also been shown 
for some other related protein such as SsADH (1R37, 24% sequence identity) 
(Esposito et al. 2003), whereas others such as PIG3 (2J8Z, 25% sequence identity) 
(Porte et al. 2009) are dimeric. These dimers correspond to the strong dimer 
interface observed in CinF, which creates the continuous β-sheet between the 
cofactor binding domains.  
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5B.1.3 CCRs contain several insertions compared to other reductases 
Comparison of CinF to homologous proteins such as PIG3 reveals some significant 
differences between the otherwise similar structures (Fig. 74A). An insertion of 
several amino acids in the cofactor binding domain of CinF leads to an elongation 
and twist by 31° of helix α14 compared to PIG3. This helix is involved in binding the 
CoA of the dimer partner and the elongation and twist places the respective residues 
(R286 and R293) in proximity to the CoA. Another insertion in CinF exists between 
helix α5 and sheet β5, which forms two additional helices α6 and α7 as well as 
another short sheet β4, whereas in PIG3 there is only a short loop. This insertion also 
plays an important role in substrate binding as the CoA is wound around helix α6 and 
held in place by several interactions with it. Another short insertion involved in CoA 
binding can be found after sheet β1, leading to the formation of a helix (α3). 
Additionally, CinF contains additional amino acids at its N- and C-terminus, which are 
forming two helices each. Yet, the role of these additional regions is not clear, as 
they are neither involved in ligand binding nor tetramer formation.  
 
The three structures of carboxylases/reductases are overall very similar, with an 
rmsd of 1.3 Å and 1.5 Å for common Cα atoms of chain A when CinF was compared 
with the CCRs from S. coelicolor (3KRT) and S. collinus (3HZZ), respectively (Fig. 
74B). These two proteins are proposed to catalyse the reductive carboxylation of 
crotonyl-CoA, whereas CinF uses octenoyl-CoA, which has a longer acyl-chain. We 
have investigated the molecular basis for the difference in substrate specificity. 
Superposition of the structures of CinF and the CCRs shows an elongated 
hydrophobic pocket for the binding of the octenoyl-chain in CinF, whereas in the 
other carboxylases/reductases no such pocket was detectable. Instead the potential 
pocket is blocked by the large residues Phe370 and Ile171 in 3KRT while the 
corresponding small residues in CinF are Gly362 and Ala163 (Fig. 74C). Thus, these 
two positions seem to determine the substrate specificity in carboxylases/reductases.  
A putative CCR from S. hygroscopicus (Accession Nr. AAR32675), which has 90% 
sequence identity with CinF, is probably also able to use octenoyl-CoA as a substrate 
as none of the changed amino acids are involved in ligand binding (Fig. 75). It also 
contains a glycine and an isoleucine at the same positions as CinF where these 
determine the substrate specificity. 
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Fig. 74: Comparison of CinF with other structures. A: Comparison of CinF (blue) with PIG3 (yellow) 
showing the insertions of CinF. B: Superposition of CinF (blue) with CCR from S. collinus (3KRT, 
green) and S. coelicolor (red), the ligands of CinF are shown as blue sticks. C: Comparison of the 
substrate binding sites of CinF (blue) and the CCR from S. collinus (3KRT, grey). The binding site of 
CinF is lined by small residues (G362 and A163), whereas this binding site is blocked by I171 and 
F370 in the CCR from S. collinus. This explains why CinF is able to use octenoyl-CoA as a substrate 
whereas the other CCRs are not. D: In SalG instead of the glycin residue there is an isoleucin residue. 
This residue was modelled into the ligand binding site of CinF (purple). It explains why SalG is able to 
use the longer Cl-crotonyl-CoA instead of the usual crotonyl-CoA. 
 
  
A B 
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Fig. 75: Structure based sequence alignment of CinF with other carboxylase/reductase 
proteins. The sequences of CinF (Streptomyces coelicolor), a putative octenoyl-CoA 
carboxylase/reductase (Streptomyces hygroscopicus), SalG (Salinospora tropica) and a putative CCR 
(Streptomyces collinus, pdb code 3KRT) were aligned with ClustalW  (Larkin et al. 2007) and 
displayed with ESPript2.2 (Gouet et al. 1999). The positions of the residues determining the substrate 
specificity are marked in yellow and with an asterisk. 
 
Another protein that has been shown to recognize a different substrate than crotonyl-
CoA is SalG from Salinispora tropica which is involved in the production of 
salinosporamides (Eustaquio et al. 2009). SalG has a 7-fold higher catalytic 
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efficiency with chlorocrotonyl-CoA than with crotonyl-CoA. SalG shares 70% 
sequence identity with CinF and a comparison of the two positions shown before to 
be important for substrate specificity indicates a different substrate binding pocket for 
this protein as well (Fig. 75). SalG also has an alanine in the same position as CinF, 
Ala163, but instead of the Gly362 in CinF or the Phe 370 in 3KRT in has an 
isoleucine. In silico modelling of this mutation into the otherwise unchanged ligand 
binding pocket of CinF allows placement of the isoleucine residue without major 
clashes in one rotamer (Fig. 74D). In this orientation the isoleucine reduces the size 
of the substrate binding pocket of CinF so that instead of octenoyl-CoA only 
pentenoyl-CoA will fit into the pocket. This agrees well with the data of Eustaquio et 
al. (2009) that chlorocrotonyl-CoA is the native substrate which has the same size as 
pentenoyl-CoA. To strengthen this hypothesis two mutants of CinF, G362F and 
G362I, have also been characterised by Liujie Huo (HIPS, Saarbrücken). These 
mutants were unable to use octenoyl-coA which underlines the importance of this 
residue. It thus seems, that by varying the size of the substrate binding pocket 
different substrates can be accommodated which leads to different substrate 
specificities of these enzymes. These findings are highly interesting for the 
generation of engineered CCRs to produce drugs incorporating uncommon extender 
units. 
 
5B.1.4 Reaction mechanism 
It has been demonstrated that CCRs carboxylate the substrate on the re side to yield 
a product with (2S)-stereochemistry, while the hydride transfer from the NADPH is 
pro-(4R) specific to the re face of the substrate (Erb et al. 2009). The arrangement of 
the substrates in the CinF structure clearly agrees with these findings suggesting a 
common evolutionary origin of carboxylase/reductases with medium-chain 
reductases. However, CCRs have evolved to bind CO2 and carboxylation is preferred 
over sole reduction of the substrate (Erb et al. 2009). Unfortunately, it was not 
possible to detect any electron density for CO2 in the CinF crystals, even after 
aeration with CO2 at high pressure. Therefore, in silico docking was used to identify a 
potential CO2 binding site. In this binding site, the CO2 is bound by hydrogen bonds 
to a glutamate and an asparagine residue and by hydrophobic interactions with a 
phenylalanine (Fig. 76A). The hydrogen bonds would increase the electrophilicity of 
the molecule, thus making it more susceptible for the nucleophilic attack from the 
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double bond of the octenoyl-CoA. The hydrophobic phenylalanine, on the other hand, 
probably restricts the binding of water in this pocket to prevent the reduction of the 
octenoyl-CoA without carboxylation.  
A few other proteins have been crystallized in complex with CO2, such as human 
carbonic anhydrase (pdb code: 2VVA) (Sjoblom et al. 2009), 2-ketopropyl coenzyme 
M oxidoreductase/carboxylase (2-KPCC, Xanthobacter autotrophicus, pdb code: 
3Q6J) (Pandey et al. 2011), phosphoenolpyruvate carboxykinase (PCK, 2PXZ, E. 
coli) (Cotelesage et al. 2007) and an Rh protein (pdb code: 3B9Z, Nitrosomonas 
europaea) (Li et al. 2007). In most structures the CO2 is located in a hydrophobic 
pocket, but bound by various binding partners such as backbone nitrogens (carbonic 
anhydrase) or arginines, lysines and tyrosines (PCK). Interestingly, in the Rh protein 
the CO2 is located in a pocket that resembles the proposed binding site in CinF (Fig. 
76B). The CO2 is bound by an asparagine residue on one side and an aspartate on 
the other, while a phenylalanine residue is found below the CO2. Additionally, there is 
a serine located in the vicinity. This supports that CO2 is most likely bound in the 
proposed binding pocket in CinF. 
 
 
 
Fig. 76: CO2 binding by different proteins. A: Proposed CO2 binding pocket of CinF. B: CO2 binding 
pocket of Rh protein.  
 
 
A B 
DISCUSSION  137 
5B.2 The thioesterase SpirTE 
5B.2.1 SpirTE causes the release of a linear product 
PKS biosynthesis relies on the covalent attachement of the growing product via a 
thioester bond to the Ppant-arm of the ACP domains of the PKS. After the last step of 
synthesis the final product has to be released from the PKS, usually by a TE domain 
that cleaves the thioester bond and often also catalyses the cyclisation of the 
product. SpirTE is the terminal domain of the spirangien-PKS cluster and causes the 
release of a linear product instead of a typical cyclised product. To understand the 
mechanism of the reaction the structure of SpirTE was solved, revealing a narrow 
substrate tunnel in which the active site is located. 
 
5B.2.2 The narrow substrate tunnel of SpirTE inhibits product cyclisation   
SpirTE shares the same overall fold with all PKS TE domains characterised so far 
(Fig. 78). A superposition with DEBS TE (36% sequence identity) (Tsai et al. 2001), 
PIK TE (28% sequence identity) (Akey et al. 2006) and TMC TE (32% sequence 
identity) (Scaglione et al. 2010) results in an r.m.s.d. of 1.6 Å, 1.7 Å and 1.9 Å, 
respectively, for common Cα atoms. SpirTE and TMC TE both catalyse the release of 
a linear product while DEBS TE and PIK TE additionally catalyse a cyclisation of the 
product. Yet, the spirangien as well as the TMC precursor molecules, which are the 
substrates for their respective TE domains, contain additional hydroxyl groups which 
would, in principle, allow cyclisation. Thus, the capability to form cyclic products or 
only linear products has to be a consequence of the structure of the TE domain. 
Even though the overall structures are similar, the size of the tunnel within the 
proteins is quite different. The tunnels of DEBS TE and PIK TE, which both catalyse 
the cyclisation of the product, are substantially wider than the tunnels of SpirTE and 
TMC TE, which release a linear product. The tunnel is very constricted in TMC TE 
and SpirTE, especially at the centre of the tunnel, where the catalytic site is located. 
This probably prevents the TE-bound substrate from looping back onto itself for 
cyclisation. The structure of PIK TE has been solved in complex with a cyclic product 
analogon 10-deoxymethynolide and as a phosphopentaketide adduct (Akey et al. 
2006). Superposition of these structures with SpirTE clearly shows that such a cyclic 
arrangement of the product would not be possible in SpirTE. The tunnel of SpirTE is 
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too narrow for such a product mainly due to the larger residues S151 and Y87 in 
SpirTE (G149 and A78 in PIK TE). In TMC TE the tunnel is constricted by S133, V67 
and additionally F182. 
It is therefore feasible that cyclisation of the spirangien and TMC precursor is 
prohibited by this bottleneck created by bulky amino acids around the active site. 
 
 
Fig. 77: Comparison of SpirTE and other TE structures. Stereo image of superposition of PKS TE 
domains. Blue: SpirTE, red: DEBS TE, green: PIK TE, ochre: TMC TE 
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Fig. 78: Comparison of SpirTE and other TE structures. A-D: Inner surface of substrate tunnel of 
TE domains (B: SpirTE, C: TMC TE, D: DEBS TE, E: PIK TE). F-G:Alignment of SpirTE (shown as 
cartoon and inner surface) with PIK TE in complex with its model product 10-deoxymethynolide (10-
DML) (F) and as phosphopentaketide adduct (G). 
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Fig. 79: Structure based sequence alignment of SpirTE with other PKS TE domains. The 
sequences of SpirTE (S. cellulosum), TMC-TE (Streptomyces sp. ck4412, pdb code 3lcr), DEBS-TE 
(Saccharopolyspora erythraea, pdb code 1kez) and PIK-TE (Streptomyces venezuelae, pdb code 
2h7x) were aligned with ClustalW (Larkin et al. 2007) and displayed with ESPript2.2 (Gouet et al. 
1999). The residues of the catalytic triade are marked by an asterisk. 
 
Another interesting feature is visible when comparing the sequences of the TE 
domains. Normally, the catalytic serine residue is found within the signature motif 
GxSxG such as GHSSG in Tautomycetin TE (TMC TE) (Scaglione et al. 2010). This 
leads to the formation of a so called catalytic elbow which makes the catalytic serine 
stand proud on the active site surface (Ollis et al. 1992). Surprisingly, the 
corresponding sequence in SpirTE is AYSSS, where the two glycines are replaced 
by the larger amino acids alanine and serine (Fig. 79). This leads to an unwinding of 
the first turn of the following α-helix α5 (Fig. 80). Whether this has any impact on the 
catalytic activity is not clear. A comparative activity assay has been performed with 
SpirTE and DEBS TE with p-nitrophenyl esters as substrates (Buntin et al. 2010b) 
and showed that the activity of SpirTE markedly increases with the substrate chain 
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length, while DEBS TE seems to be inhibited by the short chain substrates. Only with 
the pentanoyl ester could an apparent specificity constant be determined for DEBS 
TE which was about one third of the constant for SpirTE. These results indicate that 
SpirTE prefers longer aliphatic substrates as would be expected, yet it is improbable 
that the slight change in active site geometry can account for the observed difference 
in activity between SpirTE and DEBS TE. 
 
 
Fig. 80: Comparison of the catalytic serine in SpirTE (blue) and TMC TE (ochre). Due to 
changes in the catalytic site signature motif in SpirTE the nucleophilic elbow is not as pronounced as 
in other TE domains. 
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6 Conclusions and Outlook 
 
6A Virulence regulation in pathogenic Yersiniae 
RovA is the central player in a complex regulatory network involved in virulence 
factor regulation in pathogenic Yersiniae (Heroven & Dersch 2010). In this work the 
role of RovA has been elucidated biochemically and structurally. Several small 
molecules such as salicylate were found to bind to RovA with millimolar affinity. 
Further experiments revealed that binding of salicylate reduces the temperature 
dependent conformational changes observed by CD spectroscopy as well as the 
DNA binding affinity. Yet, to date it is not clear whether there really is an inducer for 
RovA. Future experiments such as mass spectrometrical analysis of capturing 
experiments from cell extracts might shed some light into the regulation of RovA by 
small molecules. 
 
Furthermore, a mutant of RovA (P98S) was discovered in certain Y. enterocolitica 
strains that was more stable in vivo than the wild type. Experiments were undertaken 
to characterize this mutant in vitro. However, it turned out that the mutant behaved 
exactly like the wild type and it was thus concluded, that the mutation probably had 
an impact on the recognition of RovA by proteases. Two other mutants (G6F and 
A10F) were designed to block the ligand binding pocket to gain insight into the role of 
ligands on the regulation by RovA. While G6F behaved like the wild type, A10F was 
significantly more stable in vitro and had lower ability to bind salicylate. Further 
studies will be carried out to investigate the impact of these mutations in vivo. 
 
It was possible to solve the structure of RovA-apo, in complex with DNA as well as in 
complex with the putative inducer molecule salicylate. These structures show that 
RovA is very flexible and can probably adopt different conformations in solution alone 
and in complex with ligands. For example, binding of salicylate induces a closed 
conformation compared to the DNA bound form which would prevent DNA binding. In 
the structure in complex with salicylate, two salicylate molecules were found in every 
monomer of RovA. One is tightly bound in a hydrophobic pocket, whereas the other 
is bound on the surface to the DBD. Comparison with structures of other MarR-type 
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proteins showed that the binding site in the hydrophobic pocket is conserved and 
probably plays an important role in the regulation of these proteins. The other binding 
site, however, was only also observed in the close homologue SlyA from S. 
typhimurium. Therefore, the physiological relevance of this binding site is 
questionable. Further studies, for example by NMR, could help to clarify this issue 
and provide insights into the conformational flexibility of RovA in solution. 
 
Additionally, the DNA bound structure revealed how RovA interacts with the DNA. 
Only few amino acids form specific interactions with DNA bases which probably 
explains the relaxed DNA sequence specificity observed for RovA compared to 
specific transcription factors like OhrR. It also shows that RovA binds to linear DNA 
and thereby possibly counteracts the DNA bending induced by its inhibitors H-NS 
and RovM. Another interesting question arose by comparison of RovA and its 
homologue SlyA from S. typhimurium. These two proteins share a sequence identity 
of 75% and in particular in the DBD these two proteins are virtually identical. 
Therefore, it is reasonable to assume they have the same DNA binding specificity. 
However, the DNA recognition sequence that has been determined for SlyA is 
distinct from that predicted for RovA. Further experiments have to be conducted to 
explain this puzzling discrepancy.  
 
The structure of the effector binding domain of RovM (RovM-EBD), an inhibitor of 
RovA, has also been solved in this study. The structure exhibited a potential small 
ligand binding pocket, which has also been described for other LTTR proteins. 
However, so far no inducer molecule is known for RovM (Heroven & Dersch 2006). 
Therefore, a transposon screen for Yersinia strains that show differences in RovA 
expression might lead to the identification of enzymes that are involved in the 
production of an inducer for RovM. This would help to understand how RovA is 
regulated by RovM. Once an inducer has been identified for RovM one could try to 
cocrystallize it with RovM. The structure of RovM in complex with its inducer would 
give insights into the conformational changes that take place upon inducer binding. 
Additionally, it would be very interesting to solve the structure of full-length RovM in 
complex with DNA as very little is known so far about the DNA binding of LTTRs and 
no structural information is available on this subject. 
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6B Polyketide synthases 
In this work the first crystal structure of a carboxylase/reductase (CinF) has been 
solved in complex with its ligands NADP+ and octenoyl-CoA. The structure grants 
insights into the novel enzymatic reaction, the reductive carboxylation without biotin 
or metal ions as cofactors, as well as provides a molecular basis for the 
understanding of the substrate specificity of this class of enzymes. Future work 
should be directed towards the introduction of mutations into typical crotonyl 
carboxylase/reductases to test whether it is possible to enhance their substrate 
specificity towards longer substrates as in CinF. It might also be possible to further 
mutate CinF to generate more space for even longer or even branched substrates. 
Additionally, the CO2 binding and activation by CinF should be target of future efforts 
as it could only be docked into the structure in this work. To this end, mutations in the 
amino acids that have been proposed to be important should be generated. Another 
worthwhile aim would be the closer investigation of TgaD, a protein that seems to 
catalyze the same reaction as CinF, yet, has only little sequence identity with it 
(Buntin et al. 2010a).  
 
By changing the substrate specificity of carboxylase/reductases it might become 
possible to allow the incorporation of unusual extender units into polyketides. 
Especially the introduction of chlorinated extender units such as in cinnabaramide 
(Buntin et al. 2010a) and salinosporamide (Eustaquio et al. 2009) can make new 
modes of actions possible for polyketide derived drugs. This would hugely enhance 
the combinatorial potential to produce new drugs with improved properties such as 
reduced resistance or higher efficacy.  
 
In order to be able to produce tailor-made drugs by changing PKS systems the TE 
domains are of importance. Several TE domains have been described that catalyze 
the cyclization of their products (Akey et al. 2006; Tsai et al. 2001). However, little is 
known about TE domains that release a linear substrate (Scaglione et al. 2010). In 
this work SpirTE, the terminal domain from the spirangien PKS biosynthesis cluster, 
has been characterized structurally. The structure showed a substrate tunnel in 
which the active site is located. Compared to substrate tunnels from cyclizing TE 
domains, the tunnel of SpirTE is much more constricted. This prevents the TE bound 
product from bending back onto itself in contrast to the findings in PIK TE where a 
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macrocycle is formed (Akey et al. 2006). A similar substrate tunnel geometry has 
also been observed for TMC TE, which also produces a linear product (Scaglione et 
al. 2010).  
 
Future work will focus on the crystallization of an inactive mutant of SpirTE in 
complex with its substrate. The structure in complex with its substrate will give 
insights into how the substrate is recognized by the protein. Perhaps, by identifying 
and mutating residues which constrict the tunnel it might become possible to allow 
TE domains that only cleave off the product also to catalyze cyclization. This might 
allow the production of completely novel compounds. 
 
Novel and optimized drugs are in strong need in these times of rising antibiotic 
resistance in bacteria and the accompanying re-emergence of pathogens that were 
believed to be defeated. 
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